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ABSTRACT

Cancer is well-recognized as an evolutionary system, as first proposed by Cairns
and Nowell more than 60 years ago. In an evolutionary context, cancers growing in vivo
typically consist of heterogeneous subpopulations of cells that interact with each other
and with host cells through selection forces operating at many temporal and spatial
scales. Moreover, the tumor environment comprises more than just cancer cells; it
includes a rich cancer stroma and cancer-driving molecules such as cytokines and
metabolites. The tumor’s environment comprises intratumoral heterogeneity that often
leads to therapy resistance attributed to the essential roles of many genetic and
nongenetic mechanisms. My dissertation investigated possible outcomes from complex
eco-evolutionary interactions between cancer cells and their host organism. By
exploring phenotypic, genetic, and epigenetic mechanisms and responses, I discovered
that both immune and non-immune resistance strategies are evolutionarily possible.
Thus, my findings from three related studies provide novel insights into the evolutionary
“arms race” of tumor progression in immune-competent and immune-deficient mice.
In the first study involving interactions between the tumor and the host immune
system, I identified the consequence of disturbing the equilibrium phase of the dynamic
process that consists of immunosurveillance and tumor progression (i.e., cancer
immunoediting). This phase is a characteristic of tumor dormancy that is achieved when
a complex equilibrium occurs between the tumor cell and the immune system, and the
viii

tumor remains in stasis. My studies have shown that perturbation of this equilibrium by
a stress stimulus, such as administration of volatile and intravenous anesthetics,
enhances tumor growth in immune-competent mice but not in immune-deficient mice.
This suggests that the immune system can be a key component in the oncological
stress response for those pharmacologic agents for hosts that are not immune
compromised.
In the second study, I identified different strategies that allow tumors to be
resistant to one type of cancer by applying selective breeding over 10 generations to
laboratory immune-competent and immune-deficient mice inoculated with subcutaneous
tumors. My studies showed that both mice strains evolved greater cancer resistance
and suppression mechanisms after 10 generations of selection, but the tumors of these
mice responded differently. In the absence of an intact adaptive immune system, the
immune-deficient mice evolved with changes in mesenchymal cells that limited
resources and cancer cell growth. In contrast, the immune-competent mice evolved with
improved immune-mediated killing of cancer cells through changes in immune cell
frequency, phenotype, and function. Cancer cells deployed observable counterresponses to the hosts’ cancer suppression mechanisms. These counter-responses
included increased proliferation in immune-competent mice and both less cell
proliferation and higher necrosis in immune-deficient mice. My studies suggest that host
species can rapidly evolve both immunologic and non-immunologic tumor defenses
depending on the lineage. However, cancer cells maintain sufficient plasticity to deploy
effective phenotypic and population-based counterstrategies quickly. For example,
variation in tumor gene expression was largely explained by the differences between
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the hosts and the fact that the hosts responded differently to selection for resistance to
the tumor.
In the third study, I examined how transcriptomic responses evolved in the hosts
in response to selection for resistance as well as the transcriptomic response of the
original cancer cell line. In immune-competent mice compared to immune-deficient
mice, I found increased expression in genes enriched for developmental processes, cell
migration and movement, and cell membrane composition. The gene with the highest
fold expression increase was Semaphorin 3D (Sema3D). This gene is implicated in the
development and formation of blood vessels during angiogenesis for the regulation of
the epithelial to mesenchymal transition. In addition, genes related to integrin binding,
cell adhesion molecular binding, and extracellular matrix (ECM) binding were
differentially expressed in immune-deficient mice. Expression levels of extracellular
matrix markers, such as collagen type VI (Col18a1), alpha, prolyl 3-hydroxylase 2
(p3h2), and collagen, type XII alpha (Col12a1), were decreased. My future plans include
associating the genome-wide differentially expressed genes with methylation changes,
as well as how examining how patterns of gene expression and methylation may
change across the tumor and the host in response to selection for cancer resistance.
The data presented here demonstrates the importance of molecular-level
mechanisms that can be effectively targeted for therapeutic benefits. Furthermore, the
mice strains developed in these studies can be used to discover more mechanisms of
tumor growth resistance and metastasis that may lead to significant advancements in
clinical treatments for patients with cancer.

x

CHAPTER 1
INTRODUCTION:
WHY CAN’T WE CURE CANCER YET?

About me
I have been a Floridian living in Tampa for 13 years, and I became an American
citizen 11 years ago. I am originally from the Republic of Sudan, a country in North
Africa. However, I was born and spent most of my early years in Saudi Arabia. After
high school, I left Saudi Arabia to attend Comenius University in Bratislava, Slovakia,
where I earned my medical degree (Doctor of General Medicine (MUDr.)). After that, I
returned to Saudi Arabia for my medical internship and residency in Obstetrics and
Gynecology. During my training and residency, I became fascinated by how research
could possibly answer many of the questions we face in the clinic. Although I was
educated and trained as a physician, I decided to pursue a career in research to answer
those questions myself after emigrating to the United States in 2001. For the next four
years, I received training and fell in love with performing research in the laboratory as a
research associate at both UT Southwestern University in Dallas, Texas, and
Georgetown University in Washington, DC. Eventually, I left Georgetown University to
join the pathology department at The University of Alabama at Birmingham (UAB).
At UAB, I had my first formal exposure to cancer research. I had the opportunity
to utilize my various in vitro and in vivo research techniques, including cell culture, DNA
1

and RNA purification, PCR, stem cell therapy, bioluminescence, fluorescence, and
optical microscopy. I was immediately hooked by the prospect that cells can survive and
thrive, despite their exposure to tremendous genetic and environmental stress. In 2008,
I was fortunate to be offered a position as a research scientist within Drs. Gillies’ and
Gatenby’s labs at the Moffitt Cancer Center. They were establishing a new program
focused on the Evolutionary Biology of Cancer using imaging and mathematical
modeling. Within this program, I gained expertise in developing and characterizing
preclinical mouse models using non-invasive imaging modalities, including ultrasound,
magnetic resonance imaging, bioluminescence imaging, fluorescence imaging, confocal
microscopy, quantitative histopathology, and immunocytochemistry. I also contributed
substantially to data analysis by combining biological data with mathematical modeling
to predict and explain the observed outcomes of our in vitro and in vivo research. My 19
years of performing laboratory-based biological research have made me comfortable
with applying modern scientific approaches that also include theoretical and technical
aspects of cancer biology. My background and training have been diverse from my early
years. My education through medical school, and exposure to different research
approaches in the laboratory give me a unique perspective. My drive, creativity as a
scientist, and passion for cancer research make me want to get up every morning to
contribute to a better understanding of cancer by using novel approaches that help
improve the management of (and potentially cure) this disease.
Several years ago, I realized that to master the theoretical background required
to understand cancer better, I needed to continue my education and pursue a PhD
degree. This led to the important question of which discipline would best help me
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understand cancer dynamics? I found the answer through my research, which had been
primarily based on finding targets in the tumor’s acidic microenvironment for therapeutic
benefits. The tumor microenvironment is an ecosystem composed of extracellular
matrices, interstitial fluids, blood vessels, stromal cells, and lastly, the cancer cells
themselves. I discovered that buffers such as sodium bicarbonate, IEPA (imidazole),
and TRIS could affect the tumor microenvironment by inhibiting carcinogenesis and
metastasis in different cancer models (Ibrahim Hashim et al. 2011; Ibrahim-Hashim et
al. 2012; Ibrahim-Hashim et al. 2011). My colleagues and I discovered that combining
buffer therapy with immunotherapy enhanced the immunotherapeutic effects by
neutralizing the acidity of the tumor microenvironment (El-Kenawi et al. 2019; PilonThomas et al. 2016; Wu et al. 2020). Strikingly, I discovered that when I altered the
microenvironment by adjusting the time or the dose of buffer therapy, I promoted the
evolution of a less-invasive cancer cell population. These findings suggested that the
tumor microenvironment selects for cells that can proliferate under the local conditions
(Ibrahim-Hashim et al. 2017). It follows that natural selection is a driving force in the
evolution of the traits of cancer. Furthermore, this evolution occurs in the ecological
context of cancer cells inhabiting and interacting with their microenvironment. Hence,
evolutionary and ecological principles are central to understanding cancer and its
dynamics. So, I decided to pursue a PhD in Integrative Biology with an area of
concentration in Ecology and Evolution at the University of South Florida.

3

What if we can use evolution- and ecology-based theories to make cancer a
friend, not a foe?
When two people are exposed to the same carcinogen, and one develops
cancer, and the other does not, an obvious question arises. Why and how did one
accomplish a victory against the onset of cancer and the other not? The answer to
these questions can be found in understanding the biological relationship between the
cancer cell and its tissue environment. Otherwise, why would the human body want to
destroy itself? My framework is not to view cancer as an enemy that needs to be
destroyed but as an uncontrolled cell growth that needs to be prevented or contained.
My goal has been to understand how to use ecology and evolution to switch the
invasive cancer cells from “malignant foe” to “benign foe”. Although the primary
approach to cancer is complete eradication, creating a scenario where the cancer
becomes a less invasive “friend” can be especially important in the context of uncurable
cancers.
More than 60 years ago, Cairns and Nowell first proposed that cancer was driven
by an evolutionary system (Nowell 1976; Cairns 1975). The importance of this
perspective has been widely recognized, particularly in the last ten years (Pressley
2021). The application of evolutionary biology has improved our understanding of
cancer progression and resistance to therapy (Greaves and Maley 2012a; Merlo et al.
2006a; Walther et al. 2015; Gatenby et al. 2009). Cancer-suppressor mechanisms have
been examined in many and diverse species of host cells, particularly in the context of
cancer incidence and body size (e.g., Peto’s Paradox )(Caulin and Maley 2011).

4

In reality, humans have a very long history of understanding the power of
selection through intentional breeding of domesticated plants and animals for desirable
traits using artificial selection. Such traits have traditionally been thought to either
emerge from existing genetic variation or arise through mutations as a source of novel
heritable variation. However, we now know that genomic-level processes are far more
complex. For example, researchers have revealed the critical role epigenetic factors
play in environmentally induced and heritable phenotypic variation (Bonduriansky and
Day 2018; Richards and Pigliucci 2021; Fargam Neinavaie 2021). Still, who could have
imagined the phenotypic diversity of domestic dog breeds from simply observing a wolf?
Human intervention has also exerted unintentional selection on organisms leading to
the rapid evolution of antibiotic, pesticide, and herbicide resistance in bacteria, insects,
and plants, respectively (Hawkins et al. 2018; Mallet 1989; Pressley 2021). So, what if
resistance to cancer growth can be evolved through generations by artificial selective
breeding?

Evolutionary arms race
Tumors growing within their hosts typically consist of heterogeneous
subpopulations of cancer cells that interact with each other and their tumor environment
(Merlo et al. 2006a). Selection acts on heritable phenotypes that allow for persistence in
local environmental conditions. In cancer, local conditions include elements of host
responses against the cancer cells. In host organisms, tumor-suppressor mechanisms
that prevent or limit the survival or proliferation of cancer cells have evolved to a greater
(e.g., elephants and naked molerats) or lesser (house mouse) extent. Cancer cells
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evolve within their hosts, and the hosts have evolved tumor-suppressor mechanisms.
These competing dynamics represent an “evolutionary arms race” where hosts evolve
over generations while cancer cells evolve de novo within each host. Since cancers die
with the host, malignant cells must re-invent strategies to overcome the species’
heritable defenses to thrive. In contrast, the host species will evolve defense strategies
over generations if tumor development limits procreation. However, all host responses
are subject to countermeasures. Cancer cells, having descended from the host’s cells,
have access to the genome from which the tumor-suppressor strategies are encoded
(Figure 1.1).

Immune and non-immune tumor-suppressor mechanisms
Emerging cancer cells must evade host responses to survive (Beatty and
Gladney 2015). The concept of immune surveillance by the host to detect and destroy
infections or cancer cells is widely accepted. It is clear there are multiple
immunosuppressive mechanisms in the tumor microenvironment (Damgaci et al.
2018c). These immunosuppressive mechanisms can significantly affect the how the
tumor can evolve within the context of the hosts ongoing innate and adaptive immune
systems. Thus, it is reasonable to assume clinically apparent cancers have already
evolved successful strategies to evade the immune response (Wellenstein and de
Visser 2018). The host also has additional tumor-suppressor strategies that rely on
mesenchymal proliferation, infiltration, and extracellular matrix deposition that manifest
within the host’s lifetime. The differences among individuals in their ability to mount this
type of tumor-suppressor response can be selected for over time, leading to human
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evolution. As with other heritable traits, tumor suppressor mechanisms may be
enhanced by the artificial selection of hosts. An important caveat is that most of these
cancers occur in people of post-reproductive ages.
The role of the host in tumor suppression is well-recognized, and several studies
have addressed the unexpectedly low cancer rates in large (e.g., whales and elephants)
and long-lived species (e.g., naked mole rats) found in nature (Brown, Cunningham,
and Gatenby 2015). Even within species, some lineages of laboratory mice entirely
resistant to injected cancer cells have been serendipitously discovered (Cui et al. 2003).
However, as explained in Chapter 4, my study is the only study that has explicitly
applied artificial selection to increase resistance to cancer in an animal.
During my thesis research, I applied evolutionary principles to breed laboratory
mice that I artificially selected to promote their resistance to a specific type of cancer
(Lewis lung cancer). One of my goals was determining feasibility – could I rapidly evolve
tumor-suppressor mechanisms in laboratory animals? Some would argue that this
would not be feasible in inbred mouse strains for in less than 10 generations using a
small number of animals. If successful, I reasoned that such experiments, when
repeated using different hosts and different tumor types, would allow me to observe a
range of tumor resistance strategies available to multicellular organisms. Finally, if the
mice evolved resistance, I could also observe the counterstrategies initiated by the
cancer cells as a response to the novel or enhanced host tumor-suppressor
mechanisms. This evolutionary tumor-host “arms race” has been anticipated
theoretically but has not been systematically investigated clinically or experimentally
(Rosenheim 2018). Therefore, my study provides a critical proof of concept. I aim to
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understand an organism’s resistance strategies to cancer and the counter-responses
that cancer cells might employ. Such an understanding may aid in amplifying a patient’s
own defenses against cancer and aid in anticipating the cancer cells’ responses once
cancer has initiated (Stankova et al. 2019).
My approach to cancer treatment involves applying ecological and evolutionary
principles. From my perspective, I view cancer as a species, carcinogenesis as a
speciation event, metastasizing cancer cells as an invasive species, and the human
body as an ecological environment. How the cancer cell alters this environment to fit its
need and how the environment reacts to suppress this growth is the basis for the
research that I am presenting in this thesis. Ultimately, with the light that my work
provides, we will continue along the path of controlling and transforming cancer from
“malignant foe” to a “benign foe”.
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Figures

Figure 1.1. Illustration of the tumor-host evolutionary arms race, this figure shows the various
tumor-suppressor mechanisms present in the tumor microenvironment: acidosisa and hypoxia
suppression, mechanical suppression, immunosuppression, and metabolic suppressions. H+ =
hydrogen ion, O2 = oxygen; ROS = reactive oxygen species.
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CHAPTER 2
EPIGENETICS AND CANCER: WHAT IS SPECIAL?

Abstract
While inherited DNA sequence information is largely finite and fixed, most living
systems must adjust to an extraordinary range of internal and external conditions to
maintain fitness. Regulatory mechanisms, like epigenetic modifications, mediate such
rapid adjustment through phenotypic plasticity, to maintain fitness in an unpredictable
environment. These dynamics include both variations in expression of genes and splice
variants that can greatly diversify available macromolecules. Epigenetic regulation is
critical for normal functions of multicellular organisms during embryogenesis and tissue
differentiation. Here, we briefly reviewed the history of epigenetics and epigenetic
mechanisms that play a role in many normal biological processes emphasizing the
similarities and the differences between those processes and cancer. We focused on
the role of epigenetic mechanisms from the perspective of ongoing ecological and
evolutionary dynamics. Although malignant cells are often viewed as simply an atavistic
return to simple single cell life forms, they typically demonstrate extensive phenotypic
variation and often retain some differentiated functions of the cells of origin. Some
collective behaviors are necessary to, for example, promote angiogenesis and
extracellular matrix remodeling. However, because tumor blood flow is often temporally
and spatially heterogeneous, cancer cells must adapt to unstable and often potentially
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lethal environmental conditions. Thus, unlike normal cells they must evolve cellular
mechanisms to successfully forage for nutrients and both avoid and defeat potential
immune predators. We discussed the role of epigenetic modifications during the
evolutionary stages of cancer development, and we explored how epigenetic alterations
vary across different cancer types and how this knowledge could be exploited for
translational and therapeutic purposes.

What is Cancer?
Cancer is often described as a “disease of the genes” (Vogt 1993). However, it
can be useful to consider cancer as a speciation event where cells that were once part
of the whole organism become the unit of natural selection (Vincent 2011; Pienta et al.
2020). The Darwinian level of selection jumps from a multicellular collective to the
individual cancer cells. That is, survival and proliferation of each cancer cell is
dependent on its fitness under current and local environmental conditions which is partly
determined by the phenotypes of competing cells. As one mechanism of inheritance,
the genome sequence, including de novo genetic mutations, provides a finite and fixed
amount of information to each cancer cell. In contrast, a cancer cell is exposed to a
wide range of environments. For example, local blood flow may drastically change over
time scales of seconds to days (Gillies et al. 2018). As cancer cells forage for often
scarce nutrients in harsh acidic environments, they must exit and move through the
complex extracellular matrix of macromolecules while maintaining vigilance for
predatory immune cells. These remarkably diverse selection forces require equally
diverse phenotypic responses which can be provided by constant regulatory
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modifications. The source of these opportunities may come from repurposing
modifications that have evolved to serve cell differentiation, tissue specialization and the
functioning of the whole organism from which the cancer originated. The repurposing of
these functions in cancer cells is quite different than those that have evolved in typical
single-celled eukaryotes (Wu and Sun 2006; Takatsuka and Umeda 2015; Beaulaurier,
Schadt, and Fang 2019) .
Epigenetic signatures in cancer cells and cancer microenvironmental cellular
components have been well documented (Pan and Zheng 2020; Hu et al. 2005; GarciaGomez, Rodríguez-Ubreva, and Ballestar 2018; Takatsuka and Umeda 2015). This
information has only recently been available thanks to advanced epigenetic sequencing
techniques(You and Jones 2012; Baylin and Jones 2011). In fact, whole-exome
sequencing of cancer cells has found inactivating mutations in genes that regulate the
epigenome (Barretina et al. 2012). For example, in the majority of low grade and
secondary high grade gliomas, mutations in isocitrate dehydrogenase 1(IDH1) produce
metabolites that increase DNA methylation (Parsons et al. 2008) resulting in an
improved prognosis (Cohen, Holmen, and Colman 2013). Advanced cancer drugs now
include those targeting methylation, and more are in clinical trials (Ganesan et al. 2019;
Cheng et al. 2019; Ghasemi 2020).
Cancer can be facilitated and initiated via two non-exclusive pathways. Up to 5%
of cancers are associated with germline mutations according to the American Society of
Cancer Oncology (ASCO). The other 95% are caused by broad environmental
carcinogens, inflammations, and viral or bacterial infections, which induce genetic and
nongenetic changes (Hyndman 2016). Current theories of cancer development are
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generally built upon the somatic mutation theory (SMT)(Migliore and Coppedè 2002),
which developed through a series of observations in the last century. Theodor Boveri
proposed that cancer is caused by chromatin changes in The Origin of Malignant
Tumors (Manchester 1995). When DNA was identified as the genetic material, Nordling
(Watson and Crick 1953) and others (Nordling 1953; Ashley 1969; Knudson 1996)
demonstrated genetic changes as signatures of cancer cells. In general, the SMT posits
cancer originates from a single somatic cell due to accumulation of multiple mutations.
An alternative to this cell-centric and gene-centric carcinogenesis model is the “tissue
organization field theory” (TOFT), which views cancer as a product of tissue
disorganization. It supposes that constant proliferation is the “normal” state of
mammalian cells, but that such proliferation is constrained by tissue controls. Disruption
of tissue control simply removes these controls and permits cells to proliferate
unconstrained, in a manner similar to early development organogenesis when the
single-celled zygote undergoes rapid cell division to form a blastula before
differentiation into the three different germ layers that give rise to different body organs
(Sonnenschein and Soto 2008). While somatic DNA mutations play a role in both
theories, the main difference is the focus for the consequence of the mutations. In SMT,
the focus is on cell phenotypes, and in TOFT on tissue phenotype.
Regardless of the specific molecular level mechanism of initiation, cancers
consistently exhibit convergent evolution to common phenotypic properties – described
as “hallmarks” in the Hanahan and Weinberg conceptual framework(Hanahan and
Weinberg 2011). Hanahan and Weinberg (2000) initially proposed six biological
characteristics that cancer cells need to acquire: unlimited proliferative capacity (cell line

15

can be immortal); insensitivity to growth suppressors; unlimited replication potential;
resistance to apoptosis; sustaining angiogenesis; ability to invade and metastasize.
Later, they added: metabolic reprogramming ability and evading the immune system.
Accelerated genetic and nongenetic alterations (often referred to as “instability”)
propels the proposed hallmarks (Hanahan and Weinberg 2000, 2011). This genomic
instability relies on the idea that “mutation rate in the early stages of tumor development
must be significantly greater than that of normal somatic cells” (Loeb and Loeb 1999).
Hence, specific genetic mutations that promote cancers have been a dominant theme in
cancer research for the past few decades. These include mutations in the tumor
suppressor gene Tumor Protein P53 (TP53). Mutations in the TP53 protein facilitate
tumor cell survival and adaptation to multiple intrinsic and extrinsic stress conditions
(Mantovani, Collavin, and Del Sal 2019). However, inactivation of tumor suppressor
genes and upregulation of tumor drivers can also be achieved without mutation but
through heritable, epigenetic alteration such as DNA methylation and histone
modifications (Baylin and Jones 2016).
New genetic sequencing techniques, along with the development of in vitro and
in vivo experiments have revealed significant spatial variations in the molecular
properties of cancer cells (Nawaz and Yuan 2016; Yuan 2016; Allam, Cai, and Coskun
2020). Comparisons within and among tumors has demonstrated how each cancer cell
population is a complex and dynamic system that interacts persistently with its
environment, constantly changing spatially and temporally (Gatenby and Vincent 2003;
Gatenby and Brown 2017; Attolini and Michor 2009). These changes can roughly be
viewed as linked ecological dynamics (changes in cancer cell phenotypes as well as
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population sizes and distributions) and evolutionary dynamics (changes in the heritable
characteristics and frequencies of the cancer cells).
While cancer biology is, indeed, complex, we propose it is not hopelessly so. In
fact, like all living systems, cancer cells and populations are governed by well-defined
principles of evolution and ecology (Nesse 2017; Nunney 2017). In fact, a cancer cell
may be simply defined as a mammalian cell that can undergo evolution (Pienta et al.
2020). That is, a fundamental requirement for evolution is that survival of an evolving
lineage is dependent on heritable phenotypes, and the way these phenotypes interact
with environmental conditions to influence fitness. However, normal mammalian cells,
as a component of a multicellular organism, ordinarily (i.e., in the absence of trauma or
infection) survive, proliferate, or die based entirely on instructions encoded within local
tissue control. This does not permit independent evolution of the cell populations within
the organism. In contrast, cancer cell survival and proliferation are, by definition,
independent of the whole tissue’s control mechanisms. The fitness of cancer cells is
entirely governed by their phenotype, the context of the local micro-environment, limiting
resources, and competitive, mutualistic and predatory cell-cell interactions. Thus,
whatever the specific mechanism, carcinogenesis is defined by transition of a
mammalian cell that cannot evolve into one that can. This evolution is facilitated by
heritable genetic and nongenetic changes to the normal functioning cell. Considering
the speed with which these changes can happen, we propose that the progressive
evolution of cancer cells relies heavily on exploiting the epigenetic programs that
ordinarily are associated with specialized tissue differentiation and function.
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History of epigenetics
The role of epigenetic mechanisms in the etiology of diseases generally and in
cancer explicitly is now widely accepted. This acceptance has been bolstered by
realizing that individual genetic defects cannot explain all diseases (Jackson et al.
2018). For example, same disease-causing mutations can result in different clinical
manifestations in monozygotic twins (Zoghbi and Beaudet 2016). Epigenetics was
described first in 1942 as the study of mechanisms by which the “genes bring about
phenotypic effects,” which results from a causal interaction between genes and their
environment through developmental processes(Waddington 1942). Since epigenetic
mechanisms can change gene expression and create variant phenotypes without
changing the DNA sequence, these mechanisms serve as a bridge that connects
genotype and phenotype (Villota-Salazar, Mendoza-Mendoza, and González-Prieto
2016; Bossdorf, Richards, and Pigliucci 2008; Richards et al. 2017; Jablonka 2017).
Waddington used the term “epigenetics” in the early 1940s, to describe the
concept that the cell begins as an undifferentiated cell type that has the potential to
develop into different cell types (Waddington 1942). Epi is a Greek word that means
“upon” or” over” so that “epigenetics” means above the genes or on top of genes,
referring to the addition of heritable characteristics mechanisms or events beyond the
genetic. Currently, epigenetics is used in a wide variety of context but generally
describes chemical changes in chromatin or transcribed DNA that can lead to change in
gene expression without any change in DNA sequence (Banta and Richards 2018;
Weigel and Colot 2012; Quadrana and Colot 2016).
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Epigenetics mechanisms and their technological revolution
Waddington (1942) vaguely defined epigenetics as a “whole complex of
developmental processes” that lie “between genotype and phenotype and connecting
them to each other.” Today, we focus on three interconnected molecular level
mechanisms, which can contribute to differences in gene expression: DNA methylation,
histone modification, and RNA interference.
DNA Methylation is the addition of a methyl group to DNA. This can modify gene
function and affect gene expression, but many methylation polymorphisms appear to
have no functional significance (Schmitz, Lewis and Goll, 2019; reviewed in Richards
and Pigliucci 2020). The methyl group is added to the carbon number 5 in the cytosine
ring in CG dinucleotide known as CpG sites, where cytosine nucleotide is followed by
guanine nucleotide in 5’ to 3’ direction and result in 5-methyl cytosine. DNA methylation
also exists in other locations, for instance, in prokaryotes N6methyladenine (6mAD). The
methyl group's addition is controlled at different cell levels and is carried out by DNAmethyl transferases enzymes (DNMTs). Different DNMTs have different roles; Dnmt1
maintains the methylation pattern and acts on hemimethylated DNA, Dnmt3A and
Dnmt3B are de novo methyltransferases and are required for methylation and
demethylation during early development. Single base pair resolution sequencing has
revealed that the amount and function of DNA methylation depends on the sequence
context (i.e., CG, CHG, or CHH where H is A, C or T) and the type of
genomic region (i.e., gene promoters, gene bodies, transposable elements (Niederhuth
et al. 2016; Richards et al. 2017).
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DNA methylation characterization methods can be categorized into studies that
evaluate global methylation, local methylation, and genome-wide methylation. Global
methylation technology was the first to be developed and focused on measuring the
total level of DNA methylation in a genome (Harrison and Parle-McDermott 2011). The
methods included measuring DNA methylation by incorporating radioactive methyl
groups into the DNA sample using S-adenosyl-L-methionine (SAM) (Balaghi and
Wagner 1993). Other methodologies used restriction enzymes that targets CG sites
across the genome (Goelz et al. 1985). Recently developed methods include
fluorescent quantification of DNA methyl groups that bind to methyl cytosine (Poloni et
al. 2013), UV-coupled high-performance liquid chromatography that detect methyl
cytosine(Kuo et al. 1980), and Enzyme-Linked-immunosorbent assay (ELISA) based
methods (So et al. 2014). Global methylation methods are limited because they cannot
detect the sequence context of the methylation or provide information about regulation
of specific genes. In addition, studies found false-positive results for some antibodybased techniques, such as errors in identifying N6methyladinine ( 6mdA) in mammals
(Douvlataniotis et al. 2020). Moreover, given that the functional importance of
methylation varies by position within the genome, global methylation lacks critical
information about location and context (Richards et al. 2017)
Local DNA methylation methods detect the methylation in a particular gene or
specific genomic regions. The first method to detect local methylation determined
differential methylation by comparing methylation-sensitive restriction enzymes and
methylation-insensitive restriction enzyme followed by either PCR amplification or
Southern blot (Ben-Hattar and Jiricny 1988; Goelz et al. 1985; Khulan et al. 2006).
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However, the gold standard method for detecting DNA methylation is bisulfite
sequencing, first introduced by Frommer et al. (Frommer et al. 1992), and then modified
by others (Clark et al. 1994; Clark et al. 2006). This method includes DNA treatment
with sodium bisulfite, which will convert unmethylated cytosine to uracil. PCR
amplification and sequencing then follow to detect the deferential conversion.
Unmethylated cytosines will be sequenced as thymine, and the methylated cytosines
will remain as cytosines. A significant problem with this sequencing approach is the
overexpression of thymine; this problem can be solved by using an algorithm that
normalizes signals from other nucleotides with the thymine signals (Leakey et al. 2008).
Bisulfite treatment kits are available and have been evaluated for their efficiency and
performance recently (Kint et al. 2018). The evaluation indicated that the use of the
digital PCR to detect methylation is the most effective approach (Kint et al. 2018).
Another method to detect global genomic and gene-specific methylation is a colorimetric
assay which uses the methyl binding domain (MBD) proteins. MBD is a magnetic
beads-based assay, where DNA is first digested with a restriction enzyme, the
generated DNA fragments are then biotinylated to generate a DNA/biotin polymer, after
that, MBD2a (a member of the MBD protein family) that had been conjugated to a
paramagnetic particle is used to select for methylated DNA. Then streptavidinconjugated horse radish peroxidase (SA-HRP) will interact with biotin and this
interaction facilitates the recognition of the enriched biotin-labelled methylated DNA.
Methylation levels are then visually evaluated via the HRP-mediated reduction of a
chromophore. One advantage is that this method can use a very low amount of DNA
(Wee, Ngo, and Trau 2015).
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The methods to detect region-specific DNA methylation changes also started
with using restriction enzymes (Frigola et al. 2002). Another method used to detect
region-specific DNA methylation changes is through immunoprecipitation of methylated
sites from chromatin using anti-methyl cytosine antibody (Me DIP)(Weber et al. 2005).
The methylation enriched sample is hybridized to a microarray or sequenced for
identification. For example, in plants (Arabidopsis thaliana), examination of genetic and
epigenetic polymorphisms between the wild accessions Colombia and Vancouver
revealed constitutive and polymorphic methylation in CGs (Zhang et al. 2008). Around
10% of analyzed CCGG sites were deferentially methylated between the two
accessions, and 8% of analyzed CCGG where constitutively methylated for both
accessions (Zhang et al. 2008). The same method was used in human breast cancer to
analyze low and highly metastatic cell lines. The study demonstrated wide hyper and
hypo methylation events in several genes including but not limited to Cadherin-1
CDH1), and Epidermal Growth Factor Receptor (EGFR) that varied metastatic ability
(Rodenhiser et al. 2008). Methylation-sensitive amplification length polymorphism (MSAFLP) is a restriction enzyme-based technique that initially relied on electrophoreses
gel for the analysis of restriction fragments (Schrey et al. 2013). However, the technique
was modified into an array-based platform that increased its output (Alonso et al. 2018).
Different Bead-Chip arrays have been developed, such as Humanmethylation27 and
HumanMethylation450 Bead Chip which focused on specific genomic regions of
interest. These arrays can probe coding and non-coding DNA regions, for characterizing
as well as developing targeted therapy. For instance, the HM450 DNA methylation kit
was used to study the primary and relapsed pediatric embryonal brain tumors (Bibikova
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et al. 2011; Bibikova et al. 2009; Carless 2015). Whole genome bisulfite sequencing to
quantify methylation at every cytosine in the genome is the most accurate method used
in humans (Lister et al. 2009) and plants (Lister et al. 2008). However, this approach is
expensive. Single-cell genome-wide detection of methylation is an even more powerful
technique that allows to detect the heterogeneity among cell populations by obtaining
the single cell genome. This approach is now available through multiple commercial kits
(Accomando et al. 2014; Kashima et al. 2020). With the acceleration in advanced DNA
methylation analysis methods, the cost is reduced, allowing for methylation to be better
quantified and studied. But there are some looming challenges with sequencing
technologies (Yoder and Tiley)
Histone modification is a post-translational modification (PTMs) to the amino
acids in histone proteins such as acetylation, methylation, ubiquitylation,
phosphorylation, and SUMOylation that occur at lysine and arginine. There are four core
histone proteins (H3, H4, H2A, H2B) that form an octamer around which DNA is
wrapped, and they are the components of the nucleosome. The nucleosome is the
fundamental unit of chromatin where DNA is packed. The core histones are globular,
except for their N-terminal tail. The PTMs of histones cause significant changes in
chromatin structure either directly, or through binding histone modifier complexes or
nucleosome remodeling complexes (Kouzarides 2007) (Suganuma and Workman
2011). Histone PTMs affect gene stability and may modify other epigenetic changes, by
recruiting chromatin modifiers, effector proteins to activate downstream signaling, and
recruiting transcriptional activators (Wysocka et al. 2006). Histone modifications are
usually detected using antibodies; however, specificity and cross-reactivity is a concern
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since there are more than 200 antibodies that recognize 57 histone modifications
(Egelhofer et al. 2011). Using microarray-based methods, the interaction of histone
modifications with the protein of interest can be screened using several peptides
simultaneously on streptavidin-coated slides spotted with biotinylated peptides (Bua et
al. 2009; Kim et al. 2006). The binding between the two peptides is visualized using
flurophore- conjugated antibody and array scanner (Lieb et al. 2001; Ho et al. 2011).
The gold standard method to study histone modifications is mass spectroscopy since it
provides quantification of specific modifications as well as specific combinations of
modifications using proteomic analysis (Völker-Albert et al. 2018; Önder et al. 2015).
New imaging techniques of PTMs of histones invitro and in vivo have been developed
using luciferase reporter (Sekar et al. 2015) and fluorescence resonance energy
transfer (FRET). With these approaches, genetically encoded fluorescent reporter (i.e.,
protein sequences that can be fused to a protein of interest to make it fluorescent) of
histone methylation can be detected by live imaging (Sato et al. 2013). Recently,
researchers introduced single-cell measurements of overall chromatin marker levels
with “epigenetic landscape profiling using cytometry by time-of-flight” or EpiTOF in
immune cells (Otto 2018). One study measured the single cell expression of eight
classes of histone PTMs in twenty-two different immune cell subsets to identify the
signature of chromatin modifications in immune cells associated with aging and
demonstrate the increase of variability between immune cells with aging (Cheung et al.
2018).
RNA-based mechanisms involved in epigenetic regulation are non-coding RNA
(ncRNA). Types of RNA mechanisms range from small ncRNAs (sncRNA), such as
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miRNAs and piRNAs, to long ncRNAs (lncRNA), such as long intergenic ncRNAs
(lincRNA), pseudogene transcripts, and circRNAs. RNAs are classified into short RNA
(smRNA ~80 bp) and long RNA (lnRNA > ~200 nucleotides). Both are found to be
involved in regulating chromatin modification and post-transcriptional processes.
Methods to detect non-coding small RNA (miRNAs) include Northern blot, in situ
hybridization, and stem-loop real-time PCR(Válóczi et al. 2004; Chen et al. 2005; Pena
et al. 2009). A recent method was developed for detection of binding of specific miRNA
using artificially designed DNA-sequence, and gel electrophoresis. This approach was
successfully tested on three miRNA sequences from different cancer types (Breast and
Lung)(Lee, Park, and Nam 2014). The results showed that various concentrations of
miRNA (aM, to nM) can be detected using this artificially designed DNA barcodes with
no need for PCR. Studies that quantified miRNA with high-throughput sequencing, and
single-cell mRNA-seq have revealed intercellular homogeneity across nineteen single
cells with identical phenotypes (Stokowy et al. 2014). A study that co-sequenced mRNA
and microRNA from the same single cell , revealed that variation of abundantly
expressed microRNAs is not correlated with expression of the predicted target (Wang
et al. 2017). Instead, micro-RNA expression variability can cause nongenetic cell- to cell
heterogeneity (Moro et al. 2019; Wang, Zheng, et al. 2019).

Roles of epigenetics in unicellular organisms, multicellular organisms and cancer
The role of epigenetics is different between unicellular and multicellular life, in
unicellular organisms, epigenetic mechanisms underlie extreme phenotypic
plasticity(Ashe, Colot, and Oldroyd 2021).This plasticity allows unicellular organisms to
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dramatically remodel their morphology and metabolism in response to changes in
environmental hazards and opportunities. In addition to this role, in multicellular
organism, epigenetic mechanisms play a critical role in channeling the specialization of
cells into different roles for the whole organisms. In multicellular organisms epigenetic
changes become heritable for a cell lineage: i.e., a skin cell becomes a skin cell, a liver
cell becomes a liver cell (Figure 2.1 A, and B).
As implicated by Waddington, epigenetic mechanisms are a critical component of
the developmental program from fertilized egg to adulthood. It ensures that within
organs, “like begets like” in the sense that progenitor cells for skin cells produce skin
cells. As an embryo develops, each cell has the same DNA and initially the potential to
differentiate into any cell type. With the progression of development, the single cell will
develop into multiple distinct cell populations organized into organs and tissues, each
with developmental features and fixed functions. This process is now believed to be
largely due to changes in gene expression caused by regulatory mechanisms (Hyland
2009). Evidence confirmed that epigenetic reprogramming includes global
demethylation during two critical steps of embryogenesis (Morgan et al. 2005).The first
is during the formation of the primordial germ cells (PGC) when genomic imprinting will
occur and result in differentiation of PGC into sperm and eggs (gametes) as
appropriate. The other is at the early embryo developmental step soon after fertilization
when the pluripotent cells differentiate into organ cells (O'Neill 2015; Kobayashi et al.
2013; Smith et al. 2012). Afterwards, a significant loss of methylation occurs from the
cells that go on to form the inner cell mass (ICM)(Smith et al. 2012). This is followed by
a round of methylation after implantation (Wang et al. 2014). A striking finding resulted
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from isolating and replanting PGC cells and pluripotent cells into embryo mice (Hayashi
et al. 2012). In this study, cells were able to differentiate into all tissue types even if they
were derived from ICM or PGC cells. PGC-like cells successfully differentiated into
gametes when transformed to gonads. This study suggested that the early PGC and
ICM embryonic cells have sufficient epigenetic flexibility to promote appropriate
development depending on their environment.
Cancer evolution has some similarities to embryonic development (Cofre and
Abdelhay 2017).In fact, there are many parallel developmental theories of epigenetics
and cancer evolution in the context of the development from one cell to a complex
structure (Cofre, Saalfeld, and Abdelhay 2019). Similar to the postembryonic
differentiation described above, carcinogenesis can be considered in the context of
epigenetic events governed by the environment (Grunau 2017). The same machinery
can activate or deactivate genes in normal cells to enhance cell proliferation, decrease
cell apoptosis and ultimately drive the cancer phenotype.
Reflecting on the perspective of cancer as a speciation event, it could be
informative to consider how epigenetic mechanisms function in microbial eukaryotes.
Epigenetics has been proposed to underlie the processes of both speciation and
phenotypic variation in microbial eukaryotes such as Paramecium and Tetrahymena
(Hall and Katz 2011). Morphological, behavioral, and molecular diversity have been
observed in ciliate genera due to mating type, conjugation, and macronuclear
development, which can be determined through genetic, epigenetic, and environmental
mechanisms. For example, tetrahymena has two types of nuclei, a somatic
macronucleus (MAC), responsible for vegetative growth that is transcriptionally active,
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and a germinal micronucleus (MIC), active only during mating (Orias, Cervantes, and
Hamilton 2011). Studies have shown that gene transcriptional activity in macronucleus
was linked to histone variant H2A.Z (Liu, Li, and GorovskyMa 1996). Also, when sexual
conjugation ensues in ciliates, micronucleus exchanges between parents, followed by
fusion, results in the diploid zygotic nucleus dividing and differentiating to form new
macro and micronuclei (Chalker, Meyer, and Mochizuki 2013). The genome of the
macronucleus undergoes DNA deletions and chromosomal fragmentation. The level of
this genome-wide rearrangement in the somatic nuclei is regulated through a N6methyladenine (6mA) DNA methylation (Coyne, Chalker, and Yao 1996; Rzeszutek,
Maurer-Alcalá, and Nowacki 2020). This methylation differs extensively between ciliate
lineages, and can result in speciation (Juranek and Lipps 2007).
In cancer, reference to a speciation event can be recognized when a cancer cell
develops a new heritable phenotype due to rearrangement or disruption of
chromosomes or genes (Pienta et al. 2020).This cancer cell then divides and evolves
into a novel species (Vincent 2010). On the other hand, others have argued that cancer
can result from aneuploidy (Duesberg and Rasnick 2000). However, this does not
explain the heterogeneity observed in cancer. We based our association of cancer to
speciation largely due to the special role of epigenetic modifications. We hypothesize
that cancer is a single cell organism that resulted from a speciation event from
the multicellular host. This single cell organism can take advantage of
reprogramming the genome. Epigenetic changes can provide a much more rapid
source of novel phenotypes than genetic mutations allowing for rapid evolution
of a new species.
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Still, epigenetic mechanisms cannot be explained without the implication of
genetics. Feinberg (2004) articulated the importance of connecting genetics and
epigenetic changes. For instance, hypomethylation or hypermethylation can activate
oncogenes and chromosomal rearrangement or affect the expression of tumor
suppressor genes (Feinberg and Tycko 2004).

Epigenetic pathways in cancer
Epigenetics changes are present in all cancers and can drive the tumor
phenotype (Baylin and Jones 2016). In figure 2.2, we summarize some epigenetic
changes in lung cancer as an example. Lung cancers have been extensively studied
(Langevin, Kratzke, and Kelsey 2015). Lung cancer develops from the interactions of
environmental, genetic and epigenetic factors(Shi et al. 2019). Genome-wide
sequencing studies have identified many genetic and epigenetic alterations associated
with lung cancer development (Hua et al. 2020; Li et al. 2015). Epigenetics changes
include DNA methylation, histone modification, and noncoding RNA.

DNA methylation
DNA methylation has been heavily studied in cancer. There are two hallmarks of
DNA methylation detected in cancer: genome-wide DNA hypo-methylation (Verma and
Srivastava 2002) (Ehrlich 2002a), and locus-specific DNA hyper-methylation (Esteller
2002). DNA hypomethylation is a common feature in all cancers, and especially in
repetitive sequences which represent two third of the human genome (Ross, Rand, and
Molloy 2010). DNA hypomethylation can result in increased gene expression, and
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studies have demonstrated that hypomethylation could be the mechanism for the
overexpression in proto-oncogene like rapidly accelerated fibrosarcoma (Raf), and MYC
proto-oncogene(c-Myc) (Barbieri et al. 1989; Hanada et al. 1993; Rao et al. 1989). In
contrast, hypermethylation can result in silencing and is specific to the promotor region
of housekeeping genes, and tumor suppressor genes which play an important role in
preventing cancer. Hypermethylated genes in cancer include retinoblastoma (RB), and
MutL homolog 1 (MLH1) in colon cancer, Breast cancer type 1 susceptibility protein
(BRACA1) in breast cancer, methylguanine-DNA methyltransferase (MGMT) in glioma
and colorectal tumors, Cyclin Dependent Kinase Inhibitor 2A (CDKN2A), Calcitonin
Related Polypeptide Alpha (CALCA), and TIMP Metallopeptidase Inhibitor 3(TIMP3) in
esophageal cancer, MGMT, and Glutathione S-Transferase Pi 1(GSTP1) in lung cancer
(Esteller, Catasus, et al. 1999; Esteller, Hamilton, et al. 1999).
Surprisingly, higher levels of methylation have also been discovered in normal
cells adjacent to tumors. For example, in esophageal cancer, the measured percentage
methylated reference (PMR) calculated for each locus was found in up to more than
5cm beyond the tumor margin in CALCA, MGMT, and TIMP3 genes. In colon cancer,
high levels of methylation in CG islands in gene promoter regions was found in normal
mucosa surrounding the tumor and benign tumors, mainly in Versican gene (Eads et al.
2001; ISSA 2000). The hypermethylation of CGs vary with tumor type and increase in
frequency by aging, which raises the idea that cancer can be a consequence of aging.
It has been shown that aging cells undergo a DNA methylation drift, this includes global
hypomethylation due to decrease or loss in DNA methyltransferase efficiency
(Hernando-Herraez et al. 2019). Also, several studies have reported overexpression of
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the de novo methylase DNMT3b in repeated DNA sequences, leading to
hypermethylation in promotor regions, such as in ARF tumor suppressors
(p14ARF) and human mutL homolog 1 (MLH1) genes (Jones and Laird 1999; Fraga
and Esteller 2007).

Histone modification
In cancer. PTMs of histone tails have been recognized globally across the
genome and in specific genes(Seligson et al. 2005). The modifications were in enzymes
responsible for either adding PTMS (i.e., writers) such as acetyltransferases,
methyltransferases, kinases, and ubiquitinases, or taking away (erasers) such as
deacetylases, phosphatases, demethylases, and deubiquitinases and consequently
changing the chromatin structure and function. Another epigenetic modification of
chromatin is the small proteins that act via domains and recognize the effector proteins
and read the histone (readers)(Bannister and Kouzarides 2011). Mutations have been
found in the genes that encode for some of the writing of histone methylation (Shen and
Laird 2013), for examples the translocation mutation occurs in the MLL gene that
encodes for H3K4methyltransferase. These studies indicate the interplay between
genetic and epigenetic mechanisms in oncogenic processes. Chromatin modifiers can
increase or decrease the level of cancer gene function, suggesting their role as tumor
suppressors as well as oncogenesis (Garraway and Lander 2013).
The most studied histone modification is histone lysine acetylation, which
weakens the interaction between the negatively charged DNA and histone. The acetyl
group's addition to histone is catalyzed by histone acetylase transferase (HATs), and on
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the opposite function, the deacetylation is catalyzed by histone deacetylase (HDACs).
Three prominent families of HATs are essential in humans: the GCN5-related Nacetyltransferase family (GNAT), the orphan family including histone acetyl transferase
CBP and P300(CBP/EP300) and nuclear receptors, and the MYST family, including
MOZ Ybf2, TIP60, and Sas2. Alterations in HATs, including mutations (deletion
translocations, amplifications and point mutations), as well as up-regulation or
downregulation without mutations have been identified in multiple cancers and
implicated in both oncogene and tumor suppressors (Mei et al. 2017). For examples, in
Acute lymphocytic leukemia, around 18% of the patients had mutations in the HAT
domain leading to loss of its activity. On the other hand, in acute myelocytic leukemia
hyper activation of HATs has been reported (Di Cerbo and Schneider 2013;
Marmorstein and Zhou 2014). HDACs include four prominent families named class I to
IV. Class III is nicotinamide adenine dinucleotide dependent, and the rest of the classes
are Zn2+ dependent. Hence, each subtype can modify multiple divergent histone sites;
each HDACs class role in individual cancer is not clearly understood. Also, the ability of
HDACs to deacetylate other proteins besides histone, such as p53, alpha-tubulin which
play a role in cancer proliferation and metastasis, makes it difficult to pinpoint the
specific effects of HDACs (Seto and Yoshida 2014).
Other histone PTMs include methylation/ demethylation of lysine and arginine
residues. Lysine methylation occurs in histone3 at lysine4 (H3K4) and is abundant in
Leukemia (Malik and Bhaumik 2010). Demethylation occurs in H3K4 and H3K9
residues via LSD1 enzyme that has been reported to be overexpressed in several
cancer types. Histone H3K27 can be either di or tri-methylated with EZH2 enzyme, one
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of the first to be overexpressed in breast and prostate cancers (Shi and Tsukada 2013).
Other histone lysine methylation has been found in cancer, such as H3K36, and H4H20
(Bannister and Kouzarides 2011; Wang et al. 2007). Atypical histone PMTs include
histone deamination, where arginine changes to citrulline, ADP-ribosylation of lysine
residues, and lysine deamination (Zhang et al. 2012). Numerous combinations among
histone PMTs have been reported, such as relationship between histone, lysine and
arginine methylation; where the expression of one PMT of H3K4me3 prevent the
deposition of the H3R2me2a mark by protein arginine methyltransferase 6 (PRMT6)
(Guccione et al. 2007) cooperative activation (Jenuwein and Allis 2001).

Noncoding RNA in cancer
Non-coding RNAs that are epigenetically related include micro-RNA, small
interfering RNA and long non-coding RNA (Kumar et al. 2020). miRNA control mRNA
translation and hence play an important role in regulating gene expression. miRNA is
also the most studied non-coding RNA(Hahne and Valeri 2018; Fernandes et al. 2019).
In carcinogenesis, the role of miRNA can be divided into tumor promoting and tumor
suppression. miR155, miR17-92, and miR21 are oncogenic and overexpressed, while
miR15-16 are downregulated(Croce 2009). Over expression of MiR146a, miR146b
downregulate BRAC1 in breast cancer (Garcia et al. 2011). Another group of noncoding
RNA that plays a role in carcinogenesis are the lnRNAs. Some of the lnRNAs are
cancer specific, such as PCGEM1 in prostate cancer and HEIH in hepatocellular
carcinoma.
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Biochemical post translational modifications in RNA i.e, RNA epigenetics or the
epitranscriptome, have been shown to be altered in cancer in the same manner as DNA
and histones, such as methylation in adenosine and cytosine (Dominissini and Rechavi
2018). However, other modifications also exist such as pseudouridine or a
hypermodified 7-deaza-guanosine(queuosine)(Barbieri and Kouzarides 2020). Esteller
et al. (2017) described epitranscriptome disturbances in cancer, specifically in writer,
eraser, and reader enzymes. Alterations included but were not limited to, the addition of
a 5′-end cap (cap), and m5C; methylation of 3' untranslated regions (UTR) of RNA
(Ramanathan, Robb, and Chan 2016; Dominissini et al. 2012). Also, m5C serves as a
crosstalk between histone and RNA via binding to chromatin modifying
complex Polycomb repressive complex 2 (PRC2). One type of cytosine-5 RNA
methylase is the NOP2/Sun (NSUN) family, which has been found to be upregulated in
some cancer types through the proto-oncogene c-Myc and downregulated in others like
skin cancer (Blanco et al. 2016; Chellamuthu and Gray 2020). RNA adenosine sites are
altered in the form of m6A and m1A. m6A plays a role in carcinogenesis by preventing
the formation of miRNAs, mainly the tumor suppressor miRNA let-7, and in metastasis
through stabilization of hairpin stem structure of lncRNA (Pandolfini et al. 2019) (Esteller
and Pandolfi 2017). The exciting and challenging part of identifying more types of noncoding RNA is the exponentially increasing number of ncRNAs and their modifier
enzymes('6 Non-coding RNA characterization' 2019) This knowledge will increase the
targets that can be clinically translated(Winkle et al. 2021).
While new experiments are fundamentally important to advance our
understanding of cancer epigenetics, the need to explore the crosstalk between all
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existing epigenetic modifications data is vital (Molina-Serrano, Schiza, and Kirmizis
2013). Some of the data needed already exists in published and publicly available
platforms (Fingerman et al. 2010). Using this existing resource will decrease the
expenses of new experiments. However, since not all data were collected and analyzed
using the same methods, the analyses will be challenging.

Targeting epigenetics in cancer
There are promising clinical implications of epigenetics control, from diagnostic,
prognostic, and therapeutic aspects (Mohammad, Barbash, and Creasy 2019; Feng and
De Carvalho 2021). Single genes known to be hypermethylated can serve as possible
biomarkers by detecting hypermethylation of those genes in tumor cells circulating
through the blood or via free DNA floating from the tumor (Locke et al. 2019).
Biomarkers are also prognostic: they monitor the tumor treatment outcome as well as
reoccurrence (Kamińska et al. 2019). Hypermethylation biomarkers have been clinically
favored over hypomethylated because heavily methylated samples can be more easily
detected (Locke et al. 2019). Hypomethylation is typically global while hypermethylation
accumulates in CG islands (Ehrlich 2002b). For example, one diagnostic biomarker is
the hypermethylation of the Glutathione S-Transferase Pi 1 (GSTP1) gene in prostate
cancer that is not found in normal prostate (Dumache et al. 2014). An example of a
prognostic marker is the microRNA 34b (miR-34b/c) gene that is hypermethylated in
lymph node metastasis of esophageal squamous cell carcinoma (Wang, Liu, et al.
2019).

35

So far, therapeutic targeting of DNA methylation is not specific, and drugs that
have been developed have mixed effects as well as side effects (Issa 2007). The FDA
currently approves two drugs: Azacitidine (5-Aza-CR) and 5-aza-2′-deoxycytidine (5Aza-CdR) for myelodysplastic syndromes (MDSs) and chronic myelomonocytic
leukemia(Palomo et al. 2018). Azacitidine is a cytosine analogue, blocks DNA
methyltransferase action leading to hypomethylation of DNA, which is a desirable effect
since genes such as CDKN2A and CDH1 have been hypermethylated in MDSs and
have been identified during disease progression. The use of small molecules targeting
specific pathways such as the p38 MAPK pathway have been developed and are in
clinical trials (Contieri, Duarte, and Lazarini 2020; Li et al. 2018).
In contrast to DNA methylation drugs, histone modification drugs have been
widely investigated in various cancer types, solid and hematological tumors (Biancotto,
Frigè, and Minucci 2010; Nepali and Liou 2021). The histone inhibitors that have been
developed include HAT, Bromodomain and extraterminal domain (BET), HDAC, HMT
and HDMT inhibitors. However, the most promising for cancer treatment are HDAC
inhibitors. Specific genes, such as p53 (Luo et al. 2000; Carlisi et al. 2008) and signal
transducer and activator of transcription 3 (STAT3) (Gupta et al. 2012) have been
sensitive to these inhibitors. For example, mice with knock outs of HDAC class I and II
died prenatally due to sever proliferation defects (Eckschlager et al. 2017), while those
with knock outs of HDAC class III died the first day post birth. Also, HDAC expression
can be specific to tumor type (Glozak and Seto 2007). For example, there is increase in
HDAC class I expression in prostate cancer (Halkidou et al. 2004), HDAC class II
expression in gastric (Choi et al. 2001), and in colorectal and cervical cancer(Huang et
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al. 2005). FDA approved HDACs inhibitors include romidepsin, Zolinza (vorinostat), and
belinostat (PXD101) for T-cell lymphomas (cutaneous T-cell lymphoma (CTCL) and
peripheral T-cell lymphoma (PTCL)). Other inhibitors are still in clinical trials and have
been reviewed recently (Zhao et al. 2020; Ho, Chan, and Ganesan 2020) (Table 2.1).
Because some of the RNA methyltransferases are similar to DNA and protein
methyltransferases already in clinical trials, RNA targeting drugs is achievable
(Sheridan 2021). This approach would be beneficial since RNAi cancer therapy is highly
specific and has a lower cost than chemotherapy (Schapira 2016). In addition, RNAmodifying enzymes, such as pseudouridine synthases, uridylases and RNA-editing
enzymes, a small-molecule inhibitor of TUT4, and inhibitors of both dsRNA and free
nucleotide (ADAR2 adenosine analogue 8-azaadenosine) have been reported (Lin and
Gregory 2015; Véliz, Easterwood, and Beal 2003). The combination of epigenetic drugs
for cancer treatments are now in clinical trials to increase efficacy and specification
(Ganesan et al. 2019).

Conclusion
Although the definition of epigenetics differs among investigators, there is no
doubt that epigenetic mechanisms play a vital role in biological process and disease
progression. Epigenetic aberrations caused by genetic mutations and environmental or
metabolic disorders can promote tumor initiation, evolution, adaptation, and metastasis
(Patel and Vanharanta 2017; Butera, Melino, and Amelio 2021). The epigenetic
changes (epimutations) during tumorigenesis are complicated and can involve multiple
steps. Understanding the interplay between genetic and epigenetic changes in cancer
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and defining which are the causes and which are the effects is yet a challenge and a
growing field to explore.
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Tables and figures
Table 2.1 Targeted epigenetics drugs in cancer

HDAC-targeted therapies
Inhibitor name

Target class
FDA Approved

Developmental status

Vorinostat (SAHA)

Pan

Panobinostat (LBH589)

Pan
Pan

FDA approved for T-cell
lymphomas, such as cutaneous
T-cell lymphoma (CTCL) and
peripheral T-cell lymphoma
(PTCL)
FDA approved for Myeloma
FDA approved for T-cell
lymphomas, such as cutaneous
T-cell lymphoma (CTCL) and
peripheral T-cell lymphoma
(PTCL)
FDA approved for T-cell
lymphomas, such as cutaneous
T-cell lymphoma (CTCL) and
peripheral T-cell lymphoma
(PTCL)
FDA approved Refractory
peripheral T cell lymphoma
(PTCL)

Belinostat (PXD101)

Romidepsin (FK228,
Depsipeptide)

Class I

Tucidinostat (Chidamide)

Class I, IIb

Clinical Trials
Mocetinostat (MGCD0103)

I, IV

Phase II/III lymphoma / Leukemia

Givinostat (ITF2357)

Pan

Phase II/III lymphoma, Leukemia
Phase II solid tumors
Phase I
phase I clinical trial—multiple
myeloma
Phase II prostate cancer
Phase I/II refractory lymphoma
Phase I
Phase I /II for myeloma
Phase I
Phase II/III B-cell lymphoma
Phase I and II clinical trials—
hepatocellular carcinoma
Phase I/II

Dacinostat (LAQ824)
CUDC-101
Quisinostat (JNJ-26481585) 2HCl
Pracinostat (SB939)

Pan
Pan

Resminostat

Class I, II, and IV
Pan
Pan
Class IIb
Class I
Class I, II
Pan

Tinostamustine(EDO-S101)

Pan

Abexinostat (PCI-24781)
AR-42
Ricolinostat (ACY-1215)
Tacedinaline (CI994)
Fimepinostat (CUDC-907)
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Table 2.1 (Continued)
Valproic acid (VPA)
Citarinostat (ACY-241)

Class I, IIa
Class IIb

Phase II in solid tumors
Phase I in myeloma

Preclinical
Trichostatin A (TSA)
MC1568
Tubastatin A HCl
PCI-34051
Droxinostat
RGFP966
M344
Tubacin
RG2833 (RGFP109)
Tubastatin A
ACY-775
Tubastatin A TFA
BRD3308
SIS17
SR-4370
TC-H 106
NKL 22
SKLB-23bb
Suberohydroxamic acid
UF010
WT161
TMP195
BG45
Santacruzamate A (CAY10683)
Nexturastat A
TMP269
BML-210 (CAY10433)

Class I and II
Class II
Class IIb
Class I
Class I
Class I

Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical

Class IIb
Class II
Class I
Class II
Class II
Class II
Class I
Class IV
Class I
Class I
Pan
Class IIb
Class I
Class I
Class IIb
Class IIa

Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical
Preclinical

Class I
Class I
Class IIb
Class IIa
Class I, II

Preclinical
Preclinical
Preclinical
Preclinical
Preclinical

Synthesis/ in vitro studies
BRD73954
CAY10603
LMK-235
Sodium butyrate
Sodium Phenylbutyrate

Class IIb
Class IIb
Class IIa
Class I, II
Class I, II

-

-
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Table 2.1 (Continued)

DNA methylation-targeted therapies.
Inhibitor name

Developmental status

Azacitidine

(5-azacitidine)

Decitabine

(5-aza-2′deoxycytidine)

Guadecitabine

(SGI-110)

5- fluro-2-deoxycytidine
(FdCyd)

5-F-CdR

Phase IV for high risk MDS
Phase III for low risk MDS,
AML with and without
complete remission
Phase II for CML
Phase IV for refractory B cell
lymphoma and T-cell
lymphoma
Phase II/III for refractory
CML, metastatic papillary
thyroid, and MDS
Phase I/II for AML and MDS
Phase II/III for advanced
hepatocellular carcinoma,
AML and CMML
Phase I for advanced cancer
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Figure 2.1. A. Epigenetics role in in unicellular organisms. In Tetrahymena vorax environmental
stresses such as bacterial abundance and high abundance of other protistan promote
phenotypic plasticity. The cell can transform from microstome to macrostome and vice versa
depending on the prey's availability. B Epigenetics role in an organogenesis process in
multicellular organism. All cell types differentiate from the epiblast, a layer that originates from
blastocyst expansion. Cells from the epiblast further differentiate to form three layers,
endoderm, mesoderm, and ectoderm. From those three layers, tissues and organs develop.
This organogenesis process is accompanied by excessive re-methylation of the genome and a
defined pattern in organ-specific gene expression. Hence, epigenetic alterations can be viewed
as constraints that accumulate through development.

54

Figure 2.2 Diagram for lung adenocarcinoma showing A. Interaction between 1) environmental
hazards such as cigarette smoking, inhaled chemicals, and pollution, 2) genetic changes such
as common mutations in p53, KRAS, EGFR, Lysine Methyltransferase 2C (KMT2C),
Serine/Threonine Kinase 11(STK11), and Kelch-like ECH-associated protein 1(KEAp1) genes
and 3) epigenetic changes such as DNA methylation, histone modifications, and non-coding
RNAi changes underlining the lung cancer progression. B. Specific alterations in epigenetics.
This includes B1. hypermethylation in genes that regulate DNA repair mechanisms, such as
Ras association domain-containing protein 1 (RASSF1A), MGMT, and OTU Deubiquitinase 4
(OTUD4), or cell cycle mechanisms such as CDKN2A/p16, or metastasis sch as Retinoic acid
receptor beta (RARβ). B2. Histone modifications such as Loss of expression and deleterious
mutations H3K9 and H3K18, overexpression in H3K36. B3. micro-RNA dysregulation in genes
that regulates apoptosis such as miR-21, miR-182, miR-374b, and miR-CHA1, or metastasis,
such as miR-1290, miR-3607-3p and miR-661.
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CHAPTER 3
IMMUNOMODULATORY AND ONCOLOGIC EFFECTS OF KETAMINE AND
ISOFLURANE ANESTHETICS IN A MURINE MODEL1

Abstract
Background: Volatile and intravenous anesthetics have been implicated in
worsened oncologic outcomes, including increased metastasis. These effects are
thought to be related to suppressed innate and adaptive immunity, decreased
immunosurveillance, and disrupted cellular signaling. The hypothesis was that
administration of anesthetics would promote lung metastasis, and this effect is
modulated by altered immune function.
Methods: Lewis lung carcinoma cells were injected into C57BL/6
immunocompetent mice and NSG (severe combined immunodeficiency) on the same
day as exposure to isoflurane and ketamine anesthetics. The mice were followed for
two weeks with imaging on days 0, 3, 10, and 14 post-tumor cell injection. On day 14,
mice were euthanized, lungs imaged ex vivo, and organs fixed in formalin for metastasis
quantification and immunohistochemistry staining. We compared the growth of the

1

This chapter has been submitted to Anesthesiology. (Ibrahim-Hashim A, Dominique
Abrahams, Robert S. Ackerman et al.) Immunomodulatory and Oncologic Effects of Ketamine
and Isoflurane Anesthetics in a Murine Model
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tumors as indexed by bioluminescent imaging over the 14 days with repeated measures
analysis of variance (rmANOVA). We compared tumor metastasis in ex vivo
bioluminescence imaging of lung, liver, with a 3-way analysis of variance, and the %
area consisting of metastasis in tissue slices from excised liver and lung with a zeroinflated beta distribution regression.
Results: Metastases were significantly greater for immunocompromised NSG
mice than for immunocompetent C57BL/6 mice over the 14-day experiment. Among
immunocompetent mice, metastases were greatest for mice receiving ketamine,
intermediate for those receiving isoflurane, and least for control mice. T lymphocyte and
monocyte infiltration was significantly decreased in anesthetic treated mice compared to
controls in immunocompetent mice
Conclusion: The immune system is the key component in the pro-metastatic
effect of administration of isoflurane and ketamine, with decreased T lymphocyte and
monocytes likely playing an important role. These effects occur during the period of the
metastatic cascade in which seeded tumor cells cluster into micro-metastases and are
more important than proangiogenic factors associated with volatile anesthesia, which
occur later.

Introduction
For many solid organ tumors, surgery provides the primary treatment method.
While curative resection is essential, there remains potential for post-operative cancer
recurrence. The spread of circulating tumor cells (CTCs) to distant tissues yields a poor
prognosis and is the primary reason for mortality in patients with cancer.(Evans, Fowler-
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Williams, and Ma 2016) In addition to stress induced by the surgical removal of tumors,
there are other perturbations to the patients’ homeostasis that can detrimentally effect
recovery and metastatic disease occurrence. Key homeostatic perturbations during the
perioperative period are associated with anesthesia, opioids, and sympathetic nervous
system agonists and antagonists.(Forget and De Kock 2009)
Significant study on the link between anesthetic agents and immune function has
demonstrated that inhaled anesthetics impact innate and adaptive immunity in several
critical ways(Kim 2018; Kurosawa and Kato 2008; Barretina et al. 2012; Sedghi et al.
2017). Volatile anesthetic agents are associated with decreased NK cell count and
cytotoxicity, increased apoptosis of T lymphocytes and decreased lymphocyte
function(Kim 2018; Kurosawa and Kato 2008; Sedghi et al. 2017; Evans, FowlerWilliams, and Ma 2016; Jiao et al. 2018; Zhao et al. 2014; Cho et al. 2017; Ackerman et
al. 2021). Isoflurane has been associated with increased gene expression of vascular
endothelial growth factor (VEGF), angiopoietin-1, and IL-8 and decreased Th1/Th2 ratio
suggesting proportionally larger disruption of cell-mediated immunity, which is important
for cancer immunosurveillance(Jiao et al. 2018; Lu et al. 2020; Ackerman et al. 2021)
The alteration of innate and adaptive immunity and proangiogenic effects of anesthetics
might potentially accelerate cancer progression.
Ketamine, commonly used as induction agent and adjunct analgesic, may also
have unintended negative oncologic effects.(Johnson et al. 2018) Reduced NK cell
activity and helper T cell count can increase the chance of tumor retention(Dang et al.
2018), possibly further exacerbated by lymphocyte apoptosis and failed dendritic cell
maturation.(Kim 2018) Ketamine has been shown to increase Treg expression and the
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CD4+/CD8+ T lymphocyte ratio, both of which inhibit antitumor immunity(Hou et al.
2016; Barretina et al. 2012) The prophylactic use of beta-blockade and
immunostimulation shows promise in blunting the immunosuppressive effects of
ketamine.(Melamed et al. 2003)
These studies and current knowledge of immunoediting, the process whereby
cancer cells are surveilled by the immune system and either eliminated or escape and
adapt under immunologic selection pressure, provide evidence suggesting there may be
a link between anesthetic-induced immunomodulation and increased cancer recurrence
and metastasis(Tedore 2015; Dunn, Old, and Schreiber 2004). The time point in the
metastatic cascade at which immunoediting plays a significant role is after
extravasation, when disseminated tumor cells (seeded CTCs) evolve to maintain
survival as micrometastases(Muncey et al. 2020).
However, the evidence of immunomodulation as the key link between anesthetic
administration and increased metastatic potential must be taken with caution because
volatile anesthetics possess other potentially pro-tumor effects. Volatile anesthetics
promote upregulation of HIFs and VEGF, important mediators of angiogenesis, which
are key for the final step in the metastatic cascade: colonization of target organs(Wall et
al. 2019; Tedore 2015). Furthermore, volatile anesthetic agents have been known to
increase the concentration of MMPs which are critical for the first step in the metastatic
cascade: local invasion and intravasation(Muncey et al. 2020; Deegan et al. 2010;
Tavare et al. 2012). Ketamine, less extensively studied in comparison, may have
undiscovered mechanisms that promote metastases.
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Studying the unintended immune and pro-metastatic effects of anesthetic agents
poses challenges. There may be difficulty in translating in vitro research to clinical
situations. In patient studies, it is difficult to control for confounding effects of cancer
staging, patient conditioning, comorbidities, and the combined effects of different
anesthetics, sedatives, and analgesics administered together. While the immune effects
described have been implicated as major contributors to the proposed pro-metastatic
effects of ketamine and isoflurane, to date investigators have not established causality.
This study aimed to bridge that gap by testing the hypothesis that anestheticinduced changes in immune function cause increased metastases. Building on
theorized effects of anesthetic agents on tumor biology via immune mechanisms, we
designed the study around the following hypotheses:
1. Isoflurane and ketamine cause an increase in tumor growth and metastases.
2. The increase in tumor growth and metastases caused by isoflurane and
ketamine is related to their effects on immune function.
We tested these hypotheses using the Lewis lung carcinoma model of lung cancer in
two groups of mice: C57Bl/6 immunocompetent mice and NSG immunocompromised
mice. In each group the effect of isoflurane and ketamine was compared against
controls that received no anesthesia. We expected that differences in metastatic load
according to anesthetic treatment would be more pronounced in the immunocompetent
mice compared with the immunocompromised mice, where they would be minimal or
absent.
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Materials and Methods
To investigate the effect of anesthetic agents on immunocompetence and
metastatic burden, we injected luciferase expressing Lewis lung cancer cells (LL/2)
intravenously into subjects of two mouse strains, one immunocompetent (C57BL/6), the
other immunocompromised (NSG). Mice of each strain received either no anesthesia
(control), isoflurane or ketamine (Figure 3.1).
Animal Models and Care
All procedures were approved, and all animals maintained under Institutional
Animal Care and Use Committee (IACUC) at H. Lee Moffitt Cancer Center (Tampa, FL).
The C57BL/6 and NSG mouse strains came from in-house breeding colonies. Original
breeding pairs for both strains were acquired from Jackson Laboratory (Ellsworth, ME).
For each of three experiments, 15 C57BL/6 (B6) and 15 NSG female mice were injected
intravenous (IV) with LL/2-luc-M38 cells at 8 weeks of age, then randomly divided
among the three anesthesia treatments (5 of each strain as control, isoflurane and
ketamine).
The NSG mice (JAX stock #005557) are immunocompromised through SCID
mutations of DNA repair proteins and other downstream regulators. These mice are B
and T lymphocyte deficient. Disrupted cytokine signaling also yields functionally
deficient natural killer cells.(Maletzki et al. 2020) When examined histologically, these
mice lack lymphoid cells in the thymus and splenic follicles, and lymph nodes appear
cellularly diminished. They provide ideal models for the study of tumor biology absent
effects from immune function.(Cata et al. 2013)
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The C57BL/6 mice (JAX stock #000664) are immunocompetent. They breed well,
have long lifespans, and are a widely used general-purpose strain. Though they exhibit
lower tumor susceptibilities, they provide an appropriate model for comparative studies
of immune function.(Sessler and Riedel 2019)
We used a syngeneic Lewis lung carcinoma cell line because of its high
tumorigenicity and compatibility with the innate murine immune system. Both immune
and tumor responses can be evaluated and quantified.(Shrestha et al. 2019)
Anesthetics and Reagents
We administered isoflurane (Henry Schein, Melville, NY) mixed with oxygen as
an inhalant at a 2-3% flow rate. We administered ketamine (80mg/kg) mixed with 10
mg/kg Xylazine (Covetrus, Portland, Me) via an intraperitoneal injection. D-Luciferin,
Sodium salt (Gold Biotech, St. Louis, MO) was prepared with sterile PBS at 15mg/ml for
bioluminescent imaging.
Experimental and Control Groups
We employed a 2 × 3 factorial design in which we crossed mouse strain
(immunocompetent C57BL/6 and immunocompromised NSG mice) by anesthetic
treatment (control, isoflurane, and ketamine). A total of 15 mice of each strain were
randomly subdivided into one of three groups (isoflurane, ketamine, control), yielding 5
subject mice per each combination of mouse strain × anesthetic. The whole experiment
was repeated three times.
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Cell Culture and Inoculation
LL/2-luc-M38 (Lewis Lung carcinoma) cells were obtained from Xenogen
Corporation (Alameda CA). The LL/2-luc-M38 cells were maintained at 5% CO2 and
grown in DMEM/F12 supplemented with 10% fetal bovine serum (HyClone) and 1% pen
strep (Corning). For cell injections, 5x105 cells in 200µL PBS was slowly injected
intravenously with a 27G needle. The ketamine treatment involved five NSG and five B6
mice receiving their cancer inoculation 10 minutes after receiving an intraperitoneal
injection (IP) of Ketamine (80mg/kg)/Xylazine (10mg/kg). The isoflurane treatment
involved five NSG and five B6 mice receiving their cancer inoculation after being put
under with Isoflurane for 10 minutes at 3% flow rate. The control treatment of five NSG
and five B6 mice simply received their inoculation of cancer cells. The ketamine and
isoflurane groups stayed under their respective anesthesia for an additional 20 minutes
post injection of cancer cells. At the end of day 0 all mice were imaged with the IVIS200 to confirm successful intravenous injections of cancer cells after intra-peritoneal
injections of Luciferase.
Mice were maintained for 14 days under standard laboratory conditions including
ad libitum food and water. During that period, they underwent intermittent fluorescent
imaging at defined time points (see “Bioluminescent Imaging”).
Tumor Growth and Metastasis
We used in vivo bioluminescence imaging over the 14-day experiment to quantify
tumor growth using the Xenogen IVIS-200 System (Perkin Elmer, Waltman, MA). Prior
to each imaging session, mice were IP injected with sterile d-luciferin at 10µl per gram
body weight. D-luciferin was prepared in PBS at 15mg/ml. After mice were injected,
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they were placed inside of an oxygen rich induction chamber consisting of 2.5-3%
Isoflurane. All mice regardless of anesthesia treatment received the isoflurane as a
necessity for performing imaging. Thus, any effects of these repeated exposures would
indiscernibly manifest across all treatment groups. The mice were then imaged for 5
minutes post injection of d-luciferin. Mice were placed on their backs with ventral side
up on the imaging platform. Anesthesia was maintained using nose cones with a 2%
isoflurane flow rate. The IVIS imaging chamber consists of a warming platform and a
cryogenically cooled CCD camera to capture both a visible light photograph of the
animals and a bioluminescent image. Imaging time points were completed at the time of
injection (time 0) and on days 3,10, and 14 post injections.
Ex vivo bioluminescence.
At day 14, mice were euthanized and ex-vivo imaging of the lungs and liver was
completed. Data were acquired and analyzed utilizing Living Imaging 4.7.4 software.
Regions of interest were defined in the chest area, in-vivo and lungs, ex-vivo to assess
the photon intensity, in photons/second (p/s).
Histology and Immunohistochemistry (IHC)
Following the ex vivo bioluminescence of the euthanized mice, we harvested
their lung, liver, and kidneys and fixed them in 10% neutral buffered formalin (Thermo
Fisher Scientific). Tissues were then processed, embedded in paraffin, and sliced into 4
- 5 µm sections. Slides from lung and liver were stained with hematoxylin and eosin
(H&E) stain and were graded by a pathologist for the presence of metastatic tissue.
According to the manufacturer's protocol, immunohistochemistry for CD3 and CD11b
antibodies on a consecutive slide from lungs was performed. Briefly, slides were
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deparaffinized on the automated system with EZ Prep solution (Ventana). Heat-induced
antigen retrieval method was used in Cell Conditioning 1 Mild (Ventana). The primary
rabbit antibody that reacts to CD3 (ab16669, Abcam, Cambridge, MA) was used at a
1:200 dilution in Dako antibody diluent (Carpenteria, CA) and incubated for 32 minutes.
The primary rabbit antibody that reacts to CD11b (#LS-C141892, Lifespan Bioscience,
Seattle, WA) was used at a 1:700 dilution in Dako antibody diluent (Carpenteria, CA)
and incubated for 28 minutes. For both antibodies, the tissue section was exposed to
Ventana OmniMap Anti-Rabbit Secondary Antibody for 16 minutes. The detection
system used was the Ventana ChromoMap kit, and slides were then counterstained
with Hematoxylin. Slides were dehydrated and placed under cover slips as per
standard laboratory protocol.
Image analysis of metastasis
We used Visio-pharm software version 2020 to measure and quantify lung and
liver metastases from the tissue cross sections of all mice. H&E images were imported
into the software and a threshold segmentation was applied to the hematoxylin channel
(with 13x13 median filter) to separate tumor and non-tumor areas. The automated
segmentation results were corrected by an experienced image-analysis technician using
the software’s manual annotation tools. For each sample, the area of tumor and tissue
were extracted from the analysis and used to determine the percentage of tissue area
comprised of metastases.
IHC quantification
IHC slides stained for CD3 and CD11b were scanned using an Aperio AT2 digital
pathology system (Leica Biosystems Inc., Vista, California) with a 20X 0.7NA objective
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lens. CD3 and CD11b positive cells were identified using size and morphology
adjustments to Aperio’s default Nuclear algorithm. The analysis provided cell counts for
each biomarker and segmented the results into four categories based on staining
intensity (0, 1+, 2+, 3+) according the Aperio’s default thresholds for scoring. Using the
percentages of positive cells for each category, H-Scores were determined for each
sample using the published formula of H-score = (% of cells stained at intensity
category 1 x 1) + (% of cells stained at intensity category 2 x 2) + (% of cells stained at
intensity category 3 x 3)(Detre, Saclani Jotti, and Dowsett 1995).
Statistical Analysis
To determine if tumor growth over the 14-day experiment varied by mouse strain
and anesthetic, we conducted a repeated-measures analysis of variance (rmANOVA)
for combined data from the 3 repeats of the experiments, using total photon flux values
for days 3, 10 and 14. We used a natural log transformation of the total flux to better
meet the assumption of normality and the exponential growth rates of the cancer cells.
We constructed a maximal model with ln(total flux) as the dependent variable, and
experiment, anesthetic and mouse strain as independent variables (main effects), day
as the repeated measure, and all two-way and three-way interactions. To run the
rmANOVA, we used package afex in program R (R Core Team 2019). Package afex
automatically applies the Greenhouse-Geisser sphericity correction to factors violating
the sphericity assumption.
To determine if the metastasis to liver and lung as measured by bioluminescence
of whole organ varied by mouse strain and anesthetic, we conducted an analysis of
variance (ANOVA) of the ex vivo organ photon flux for the combined data from the three
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repeats of the experiment. We used a natural log transformation of total flux to better
meet the assumption of normality and to linearize exponential growth of the cancer
cells. We initially constructed a maximal 4-way ANOVA with ln(total flux) as the
dependent variable, and experiment, anesthetic, mouse strain, and organ type as
independent variables (main effects), and all possible interactions of the main effects.
We simplified the models by eliminating non-significant interactions found in the
maximal model. The final model included ln(total flux) as the dependent variable,
experiment, mouse strain, and organ type as main effects, and the interactions of
experiment × mouse strain, experiment × organ and mouse strain × organ type.
To determine the effect of experiment, anesthetic, mouse model, sampled organ
(liver or lung), and interactions of these variables on the proportion of tissue sample
consisting of metastasis we conducted a zero-inflated beta distribution regression.
Because the response variable included numerous zero values (zero-inflated), we
conducted an analysis that uses a piecewise distribution to model both the probability
that there is no metastasis (prY=0), as well as the effect of each predictor variable on
the magnitude of metastasis when y>0. To accomplish this, we used a Bayesian
inference for zero-inflated beta regression (zoib) model run with package zoib (version
1.5.1) in program R (R Core Team 2019)(Liu and Kong 2015). The model was run with
2 chains, 1,000 iterations burn-in, 20,000 iterations post burn-in, and thinning set to 20.
Convergence of the chains was checked by inspection of trace plots and the potential
scale reduction factors(Gelman 1992).
To determine effects of anesthesia treatment on CD3 and CD11b staining in
C57BL/6 mice, we used a one-way between subjects analysis of variance (ANOVA). A
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Dunnett’s test identified the pairs of treatments that showed significant differences. NSG
mice were excluded from this analysis owing to their lack of mature T and B
lymphocytes, which preclude positive staining in tissue sections.

Results
Tumor growth and metastasis
Bioluminescent imaging: On inspection of whole organism bioluminescence,
immunocompetent C57BL/6 mice had significantly lower metastatic burden than the
immunocompromised NSG mice (Figure 3.2A). In immunocompetent C57BL/6 mice,
anesthetic treatment with ketamine significantly increased the metastatic burden in
comparison to other treatment cohorts. For immunocompromised NSG mice, metastatic
burden did not vary with anesthesia treatment (Figure 3.2A). Ex-vivo representative
images from lung, liver, and kidneys from each cohort in each strain illustrate the same
in vivo results and illustrate higher metastasis to lungs in comparison to liver and kidney
(Figure 3.2B).
The rmANOVA of tumor growth (total flux) over time identified significant effects
of experiment, mouse strain, and anesthetic, and a significant effect of day, the
repeated measure (Table 3.1). Tumor growth was significantly greater in mice of the
second repeat of the experiment than in the other two. Tumor growth rates were
significantly greater in the NSG mice than in the C57BL/6 mice, and tumor growth rates
were significantly greater in mice administered ketamine and isoflurane compared to
control mice.
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The rmANOVA revealed significant two-way interaction effects of experiment ×
mouse strain, experiment × anesthetic, experiment × day, and mouse strain × day
(Table 1). Two of the three-way interactions were significant: experiment × mouse strain
× day, and mouse strain × anesthetic × day (Table 3.1). The significant interactions
indicate that the greater tumor growth in immunocompromised NSG mice than for
immunocompetent C57BL/6 mice (Figure 3.3A) was contingent on time but significantly
less contingent upon the anesthetic treatment (Figure 3.3B).
Ex vivo bioluminescence
The ANOVA model of ex vivo tumor burden (photon flux) provided a good fit to
the data (multiple R2 = 0.589). Ex vivo tumor burden showed significant effects of
experiment, mouse strain, and organ type, but not anesthesia treatments (Table 3.2).
The interactions of experiment × mouse strain, experiment × organ, and mouse strain ×
organ type was also significant (Table 3.2). Ex vivo tumor burdens were significantly
greater in experiment 2 than the other two experiments, greater in NSG than C57BL/6
mice, and greater in lung than in liver. The significant interactions indicate that the
differences between the two mouse strains’ ex vivo tumor burdens were contingent
upon both experiment and organ. The relatively greater ex vivo tumor burden in NSG
than in C57BL/6 mice was more pronounced in experiment 2 than the others (Figure
3.4A). The greater ex vivo tumor burden in the lung than in liver was less pronounced in
NSG than in C57BL/6 mice (Figure3. 4B).
Image analysis of metastasis
The zoib model indicated that the proportion of tissue consisting of tumor
metastasis differed among experiments, between mouse strains, and between organ
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types, but did not differ among the anesthetic treatments (Table 3.3). The 95% credible
interval for the beta regression coefficients for Experiment 2 do not overlap 0, indicating
that the proportion of tissue consisting of tumor metastasis was greater than Experiment
1. This difference most likely resulted from differences in the success of initial LL2 cell
inoculation and will not be considered further. The 95% credible interval for the beta
regression coefficient for NSG mice did not overlap 0, indicating that the proportion of
tissue consisting of tumor metastasis in individuals of NSG mice was significantly
greater than for C57BL/6 mice. Finally, the 95% credible interval for the beta regression
coefficient for lung tissue samples did not overlap 0, indicating that the proportion of
tissue consisting of tumor metastasis in samples of lung tissue was greater than in
samples of liver tissue.
The zoib model indicated that anesthetic type had no effect on the absence of
cancer in the tissue sample (0% proportion tissue consisting of tumor metastasis), but
samples from lung were less likely than samples from liver to exhibit no cancer (Table
3.3).
Histology and Immunohistochemistry (IHC)
Sample histological H&E staining of lungs from C57BL/6 are shown in Figure 3.
5A and from NSG mice in Figure3. 5B. Because NSG mice lack mature T and B
lymphocytes, we did not observe any positive stained cells in the lung sections (Figure
3.6 A and B). Because C57BL/6 mice have an intact immune system, we observed
positive cell staining in lung sections. When comparing the three anesthesia treatments,
CD3 staining indicated that the T cell counts were significantly lower for ketamine and
isoflurane treatments than for the control (F2,6 = 14.86, p = 0.0047) (Figure 3.7A and
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B). CD11b staining indicated that monocytes are present in NSG and C57BL/6; hence,
positive staining was detected on lung sections from both strains in the three treatment
groups. No significant changes were observed between anesthesia treatment groups in
NSG mice (Figure 3.8 A and B); in C57BL/6 mice, in contrast, the index for monocytes
was significantly lower for ketamine and isoflurane treatments than for controls (F2,6 =
25.59, p = 0.0012) (Figure 3.9A and B).

Discussion
The current study was designed to address the question of immunomodulation
as the causal link between anesthetic agent exposure and increased metastatic
potential, by using an NSG strain of mice lacking lymphocytes or functional NK cells.
We discovered significantly increased metastatic burden associated with ketamine and
isoflurane treatment, most pronounced with ketamine. Ketamine and isoflurane
accelerated tumor growth in immunocompetent mice. This is quite extraordinary when
considering the only difference in the ketamine and isoflurane treatment arms compared
with controls was a 30-minute exposure to each respective anesthetic during tumor cell
dissemination, and measured outcomes spanned 14 days. That immunocompromised
NSG mice demonstrated increased overall metastatic burden throughout the time
course of the study compared with the immunocompetent cohort was expected given
the known mechanisms of immune function in cancer surveillance(Dunn, Old, and
Schreiber 2004). By day 14, there was no difference between the control mice versus
anesthetic treatment arms in the immunodeficient cohort and tumor growth was not
dependent on anesthetic choice. Alternatively, tumor growth in immunocompetent mice
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was dependent upon anesthetic choice and increased with ketamine and isoflurane
over time. These observed effects taken together indicate the primary mechanism of
anesthetic-mediated increase in tumor growth and metastatic burden for both agents
was immunomodulation.
This corroborates previous findings from a study that evaluated ketamine and the
volatile anesthetic halothane and found that both increased metastases, ketamine more
so than halothane, in a MADB106 rat model of metastasis by tail vein injection. The
study allowed for 1 hour of anesthetic exposure and MADB106 tumor cells were not
injected until 4 hours after the anesthetic was terminated(Melamed et al. 2003). Our
study, on the other hand, performed tail vein injections during anesthesia (10 minutes
into 30 minutes total exposure time) to better simulate the true surgical environment,
whereby tumor cells are shed during surgical resection under anesthesia.
Another key difference between this study and predecessors was the inclusion of
the second arm whereby the same set of experiments was performed on the NSG
immunocompromised strain of mice. If the anesthetic-induced increase in metastases in
immunocompetent C57BL/6 mice was truly immune-mediated, we would expect
application of the same experiment to immunodeficient NSG mice would result in no
difference in metastases between the ketamine and isoflurane groups versus controls.
And indeed, this is what was observed.
Ex vivo imaging of lungs and liver did not show significant differences based on
anesthetic agent, and so further evaluation with histology and immunohistochemistry
was performed. This revealed that treatment with each anesthetic agent correlated with
differences in lymphocyte and monocyte infiltration. Mice who received ketamine and
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isoflurane had significantly less T cells based on CD3 staining compared with control
mice in the immunocompetent cohort. Ketamine was associated with a larger decrease
in T cells than isoflurane. Monocytes were also decreased in the immunocompetent
mice who received isoflurane and ketamine compared to controls based on CD11b
staining and isoflurane was associated with a larger decrease than ketamine. On the
other hand, there was no significant difference in monocytes in the NSG mice, which
are devoid of mature lymphocytes. The inverse correlation of T lymphocytes and
monocytes in immunocompetent mice receiving either anesthetic agent, and lack of
correlation in the immunocompromised mice, indicates that ketamine and isoflurane are
likely altering immune function. Innate and adaptive immunity are uniquely complex and
interwoven, and these findings suggest that each anesthetic increases the metastatic
potential of injected Lewis lung carcinoma via disrupted immune function.
The metastatic process is marked by considerably inefficiency and previous
authors have described how these inefficiencies create temporal patterns in
metastasis(Cameron et al. 2000; Gomis and Gawrzak 2017; Micalizzi, Maheswaran,
and Haber 2017). A model of lung metastasis of melanoma in C57BL/6 mice found that
after tail vein injection, multicellular tumor clusters were not detected in lung until 4 days
post-injection, with only single disseminated tumor cells detected prior(Cameron et al.
2000). In our study, tumor cells were injected during anesthesia and a significant
difference in metastatic burden between isoflurane or ketamine and controls in C57BL/6
mice was not seen until 10 days post injection. Statistical analysis of images of
metastases revealed that the distribution of metastases did not differ between ketamine,
isoflurane, and controls, thus the areas that originally seeded with tumor cells were the
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same areas that developed metastatic burden. These findings provide more evidence
that angiogenic factors, which develop after tumor cells begin to cluster were not as
important as factors affecting immunosurveillance. In the study by Melamed et al
MADB106 cells were injected 5 hours after ketamine was administered for one hour
total, and they found a significant increase in metastases 3 weeks later(Melamed et al.
2003). This is also consistent with the timeframe where immunoediting would be a
significant factor in preventing metastasis.
The key strength in this study was the overall design since to date, no groups
have used an immunological control group to confirm the theory that anesthetic agents
increase metastases via immunomodulation. Significant care and detail were made to
ensure well-controlled environmental factors, elimination of potential confounders, and
statistical rigor of the analyses. This study and others like it are limited in that tail vein
injection of tumor cells bypasses the first stage of the metastatic cascade: local invasion
and extravasation. Another limitation is that the logistics of imaging required each
mouse to be briefly anesthetized with isoflurane during imaging. Any confounding from
this effect was distributed evenly across all experimental and control mice as every
mouse was imaged the same way. While preclinical studies have the advantage of well
controlled experimental design and conditions, the downside is that data may not be
directly applicable to humans. Immunohistochemistry staining only gives data on the
presence of certain immune cells but does not provide information on their functionality.
The current study provides compelling evidence that the immune effects of
isoflurane and ketamine may be more important than other known or theorized
mechanisms of increased metastatic potential, such as increased VEGF and HIFs in the

74

case of volatile anesthetics. Furthermore, the overall quantity of metastases in the
immunocompromised mice was significantly higher by several orders of magnitude at all
time points investigated compared with the metastatic burden seen in the isoflurane and
ketamine C57BL/6 groups. This suggests that immunoediting as it relates to tumor
elimination is impaired by these agents but not to entirety.
Future experiments will delve deeper into understanding the temporal aspects of
pro-metastatic effects by administering anesthetics at differing timepoints before or after
tail vein injection to evaluate the response. We also plan to use functional
immunoassays to better understand how different anesthetic agents alter immune cell
function. We plan to evaluate orthotopic primary tumors and simulate surgical resection
under anesthesia to better simulate the true surgical environment and include the first
steps of the metastatic cascade (local invasion and extravasation).
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Tables and figures
Table 3.1. Repeated measures analysis of variance examining effects of experiment (Expt),
mouse strain (C57BL/6, NSG), and anesthesia treatment (anesthetic: control, isoflurane,
ketamine) on whole organism bioluminescence (photon flux) over course of experiments.
Effect
Between Subjects
Expt
Mouse Strain
Anesthetic
Expt×Mouse Strain
Expt×Anesthetic
Mouse Strain×Anesthetic
Within Subjects
Day
Expt×Day
Mouse Strain×Day
Anesthetic×Day
Expt×Mouse Strain×Day
Expt×Anesthetic×Day
Mouse Strain×Anesthetic×Day

Df

MSE

F

P

2, 66
1, 66
2, 66
2, 66
4, 66
2, 66

1.25
1.25
1.25
1.25
1.25
1.25

67.94
462.87
5.69
4.43
4.41
1.21

<0.001
<0.001
0.005
0.016
0.003
0.306

1.84, 121.33
3.68, 121.33
1.84, 121.33
3.68, 121.33
3.68, 121.33
7.35, 121.33
3.68, 121.33

1.03
1.03
1.03
1.03
1.03
1.03
1.03

337.21
6.84
42.75
1.88
7.28
1.41
2.55

<0.001
<0.001
<0.001
0.124
<0.001
0.203
0.047
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Table 3.2. Analysis of variance on effects of experiment (Expt), mouse strain (C57BL/6, NSG),
and organ (liver, lung) type on ex vivo bioluminescence (photon flux).

Effect
Expt
Mouse Strain
Organ
Expt×Mouse Strain
Expt×Organ
Mouse Strain ×Organ
Residuals

df
1
1
1
1
1
1
153

Sum Sq
68.7
11140.9
509.5
112.5
72.6
53.4
1361.6

Mean Sq
68.7
11140.9
509.5
112.5
72.6
53.4
8.9

F
7.72
128.21
57.25
12.64
8.16
6.00

P
0.006
<0.001
<0.001
0.005
0.004
0.015

79

Table 3.3. Posterior inferences of the coefficients (on the logit-scale) in the best Bayesian zeroone-inflated beta distribution model on proportion of tissue area with tumor metastasis. The first
model component estimates the mean (linear predictor) in the model, and the second
component the probability of zero. The factor levels ‘Experiment 1’, ‘Control’ (anesthetic),
‘C57BL/6’ (mouse strain) and ‘Liver’ (organ) are the baseline values in the model and are
included in the intercepts.
Model
Component
Logit(mean)

Coefficient

Mean

25% quantile

97.5% quantile

Intercept*
Experiment 2*
Experiment 4
Isoflurane
Ketamine
NSG*
Lung*
Isoflurane:NSG
Ketamine:NSG
NSG:Lung
Isoflurane:Lung
Ketamine:Lung

-4.338
0.918
0.221
0.030
0.527
1.768
2.544
0.284
0.135
0.494
-0.490
-0.809

-5.133
0.531
0.074
-1.066
0.584
0.966
1.607
-0.639
-0.699
0.366
-1.403
-1.698

-3.568
1.246
0.567
1.172
1.685
2.637
3.560
1.067
1.158
1.293
0.402
0.230

logit(Pr(y = 0))

Intercept
Isoflurane
Ketamine
Lung*

-0.419
-0.165
-0.033
-2.609

-1.113
-1.266
-1.012
-4.016

0.0463
0.864
1.111
-1.406

d
2.131
1.880
2.454
d -- Regression coefficient in the linear predictor for the sum of the two shape parameters in the beta
distribution
* -- indicates a significant difference when the quantile range does not overlap zero
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Figure 3.1 –Study Design. Lewis lung carcinoma (LL-2-Luc-M38) cells were injected via the tail
vein into immunocompetent C57BL/6 and immunodeficient NSG mice. Within each population,
one group was kept without anesthesia administration (CTR). One group was administered
volatile anesthesia with isoflurane, and one group was administered intraperitoneal ketamine.
Using bioluminescence methods, the mice were imaged on days 0, 3, 10, and 14 post tumor
cells injection.

81

Figure 3.2 -Bioluminescence images. A. In vivo representative bioluminescence ventral view
images of mice from the three treatment cohorts; control, Isoflurane, and Ketamine in C57BL/6
and NSG strains. Images are at day 14 post-injection. Bioluminescence signal is more visible in
ketamine treated mice in C57BL/6 strain compared to other treatment groups. Bioluminescence
signal is equally visible in all treatment groups in the NSG strain. B. Ex vivo representative
images of the lung (red arrow), liver (blue arrow), and Kidneys (green arrows) from the three
treatment cohorts for C57BL/6 and NSG strains. Note different scale bars in C57BL/6 and
NSG.
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Figure 3.3- Quantification of anesthetic effect on metastasis A. Natural log of total flux based on
bioluminescence imaging of whole organism for C57/BL6 and NSG mouse subjects. B. Natural
log of total flux based on bioluminescence imaging of whole organism over the 14-day course of
the experiment for C57/BL6 and NSG mouse subjects contingent upon anesthesiology
treatment
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Figure 3.4- Quantification of experiment and mouse strain effect on ex vivo metastasis A.
Natural log of total flux based on ex vivo bioluminescence imaging of lung and liver for C57/BL6
and NSG mouse subjects. B. Natural log of total flux based on ex vivo bioluminescence
imaging on day 14 of lungs and liver for C57/BL6 and NSG mouse subjects contingent upon
mouse strain.
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Figure 3.5- Representative histologic images (H&E staining) of lung and liver metastasis.
A. Carried by immunocompetent C57/Black/6 mice and B. Carried by immune-compromised
NSG mice. The representative images are from the three treatment cohorts; the upper panels
are treated with no anesthesia CTR, the middle panels are treated with isoflurane, and the lower
panels are treated with Ketamine. Representative high-power fields with inset low-power images
of the whole tumor cross-section are shown. Red arrows are directed to normal tissue, blue
arrows are directed to metastatic tissue.
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Figure3.6- CD3 staining and quantification in NSG mice. Representative images of
immunohistochemistry staining of CD3 in lungs of A. NSG mice. Images are from the three
treatment cohorts (CTR, Isoflurane, and Ketamine) and contain representative high-power fields
with inset low-power images of the entire tumor cross-section. Positivity mask in lower
panels. Percent positive cells quantified over an entire viable area of lung cross-section
of B. NSG mice. Mean±SEM, n=3 mice each arm. One-way ANOVA, (F2,6 = 14.86, p =
0.0728). p=0.0796 vs. CTR group.
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Figure 3.7- CD3 staining and quantification in C57BL/6 mice. Representative images of
immunohistochemistry staining of CD3 in lungs of A. C57/BL6 mice. Images are from the three
treatment cohorts (CTR, Isoflurane, and Ketamine) and contain representative high-power fields
with inset low-power images of the entire tumor cross-section. Positivity mask in lower
panels. Percent positive cells quantified over an entire viable area of lung cross-section
of B. C57/BL6. Mean±SEM, n=3 mice each arm. One-way ANOVA, (F2,6 = 14.86, p = 0.0047).
**p<0.0029 and *p<0.0495 vs. CTR group.
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Figure 3.8 - CD11b staining and quantification in NSG mice. A. Representative images of
immunohistochemistry staining of CD11b in lungs of A. NSG mice. Images are from the three
treatment cohorts (CTR, Isoflurane, and Ketamine) and contain representative high-power fields
with inset low-power images of the entire tumor cross-section. Positivity mask in lower
panels. Percent positive cells quantified over the entire area of lung cross-section of B. NSG
mice. Mean±SEM, n=3 mice in each arm. One-way ANOVA, (F2,6 = 0.5066, p = 0.6262).
p=0.6667 and p=0.5752 vs. CTR group.
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Figure 3.9- CD11b staining and quantification in C57BL/6 mice. A. Representative images
of immunohistochemistry staining of CD11b in lungs of A. C57/BL6. Images are from the three
treatment cohorts (CTR, Isoflurane, and Ketamine) and contain representative high-power fields
with inset low-power images of the entire tumor cross-section. Positivity mask in lower
panels. Percent positive cells quantified over the entire area of lung cross-section of B. C57/BL6
mice. Mean±SEM, n=3 mice in each arm. One-way ANOVA, (F2,6 = 25.59, p = 0.0012).
***p<0.0008 and **p<0.004 vs. CTR group.
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CHAPTER 4
ARTIFICIALSELECTION FOR HOST RESISTANCE TO TUMOR GROWTH AND
SUBSEQUENT CANCER CELL ADAPTATIONS: AN EVOLUTIONARY ARMS RACE 2

Abstract
Background: Cancer progression is governed by evolutionary dynamics in both
the tumor population and its host. Since cancers die with the host, each new population
of cancer cells must re-invent strategies to overcome the host’s heritable defenses. In
contrast, host species evolve defense strategies over generations if tumor development
limits procreation.
Methods: We investigate this “evolutionary arms race” through intentional
breeding of immuno-deficient SCID mice and immuno-competent Black/6 mice to evolve
increased tumor suppression. Over 10 generations, we injected Lewis lung mouse
carcinoma cells [LL/2-Luc-M38] in a cohort of each mouse accession and selectively
bred the two individuals with the slowest tumor growth at day 11. Their male progeny
was then used as hosts in the subsequent rounds.
Results: The evolved SCID mice suppressed tumor growth through
biomechanical restriction from increased mesenchymal proliferation, and the evolved

2

This chapter has been previously published, open access, in Br J Cancer. (Ibrahim-Hashim A,
Luddy K, Abrahams D, Enriquez-Navas et al.) Artificial selection for host resistance to tumour
growth and subsequent cancer cell adaptations: an evolutionary arms race. Br J Cancer. 2021
Jan;124(2):455-465, https://doi.org/10.1038/s41416-020-01110-1, and is reproduced under the
Creative Commons license.
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Black/6 mice suppressed tumor growth by increasing immune-mediated killing of cancer
cells. However, transcriptomic changes in LL/2-Luc-M38 cells, including expression of
genes associated with multicellular tissue organization and function, allowed resumption
of growth through increased matrix remodeling in the SCID mice, and reduced
angiogenesis, increased energy utilization, and accelerated proliferation in the Black/6
mice.
Conclusion: We conclude that host species can rapidly evolve both immunologic
and non-immunologic tumor defenses. However, cancer cells maintain sufficient
plasticity to quickly deploy effective phenotypic and population-based counter
strategies.

Introduction
Cancers growing in a wide range of hosts typically consist of heterogeneous
cellular subpopulations that interact with each other and their environment (Merlo et al.
2006a). For the cancer cells, phenotypes and the corresponding genotypes that are
most able to take advantage of local environmental conditions will proliferate. The
selective environment of the host includes elements of host responses. In host
organisms, evolution can select for tumor suppressor mechanisms that prevent or limit
the survival and proliferation of cancer cells. These competing dynamics are often
termed an “evolutionary arms race.”
The description of cancer as an evolutionary system; first proposed by Cairns
and Nowell more than 60 years ago (Nowell 1976; Cairns 1975), has been well
recognized particularly in the application of evolutionary biology to understand cancer
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progression and resistance to therapy (Greaves and Maley 2012b; Merlo et al. 2006a;
Walther et al. 2015; Gatenby et al. 2009). In diverse species of hosts, cancer
suppressor mechanisms have been examined, particularly in the context of cancer
incidence and body size (e.g., Peto’s Paradox (Caulin and Maley 2011)). However, we
are not aware of prior studies that explicitly applied selection to increase an animal
species’ resistance to cancer.
Evolution can be driven by human or “artificial” selection through intentional
breeding of domesticated animals for desirable traits that are evolutionarily feasible
within the underlying genome(Thomas et al. 2020). For example, the phenotypic and
genetic diversity of the domestic dog diversified from that of the wolf genome. Human
intervention can also exert unintentional selection on organisms leading to dramatic
evolutionary changes such as antibiotic or pesticide resistance (Allendorf and Hard
2009).
Here we hypothesize that, with application of appropriate selection forces,
laboratory animals can evolve phenotypes that are resistant to the growth of implanted
tumors providing insights into available tumor suppression strategies. To examine the
range of potential tumor suppression strategies, we examined the artificial evolution of
resistance in immuno-competent and immuno-deficient mice.

Methods
Animal Models and Care
All animal studies completed where approved and maintained under University of
South Florida’s Institutional Animal Care and Use Committee (IACUC) at H. Lee Moffitt
Cancer Center (protocol reference numbers 2014R, 0061R, and 3735R). Animals were
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maintained in accordance with IACUC standards of care in pathogen free rooms, in the
USF Vivarium on site at the Moffitt Cancer Research Center (Tampa, FL). For
bioluminescence imaging, Isoflurane was used as the anesthesia for the mice. For
effect, the mice, were induced under 3% Isoflurane and maintain for the duration of the
imaging at 1.5% Isoflurane. Oxygen flow rates were kept between 0.25 and 0.5
L/minute.
CO2 inhalant is used for humane euthanasia. During euthanasia, mice were
placed in a chamber or kept in their home cage when possible. CO2 was turned on with
the use of a flow meter which ensured an appropriate displacement rate of air inside the
enclosure by displacing 10-30% of the chamber volume per minute. A secondary
physical method of euthanasia was completed by cervical dislocation
We used both C57BL/6 and SCID/beige mice accessions. The original breeding pairs
for both accessions were acquired from Charles River (Wilmington, MA). From each
generation, 10 weaned C57BL/6 (Black/6) and 10 weaned SCID/beige (SCID) male
mice were injected on the right flank with LL/2-luc-M38 cells at 6 weeks of age. Females
from the same pool of offspring as the males were kept for breeding.
Because the LL/2-luc-M38 cells grow very rapidly, often killing the host by day
25, we selected animals for breeding based on the tumor growth at day 11 following
injection. This was necessary to allow sufficient time for the animal to breed
successfully (i.e. prior to the time in which the tumor burden precluded successful
mating). The male with the smallest tumor of the 10 injected mice was bred with 4
females and the male with the next smallest tumor was bred with two other females.
This procedure was repeated for twelve generations. Mice were imaged with the In Vivo
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Imaging System 200(IVIS-Spectrum 200; Caliper Life Sciences, Waltham,
Massachusetts) at the time of injection (time 0) and on days, 7 and 14 post injections.
Tumors were also measured with calipers twice a week. In some experiments after
generation 10, we continued to measure tumors until day 28 to examine the durability of
the host tumor suppression.
To explore the mechanisms underlining the generated evolved mice we
purchased 10 males of C57BL/6 and 10 males of SCID mice. These are referred to as
Non-evolved Black/6 and Non-evolved SCID. At 6 weeks of age we injected 10 mice of
each accession subcutaneously into the right flank with LL/2-luc-M38 cells. At the same
time, we injected LL/2-luc-M38 cells into 10 male mice from generation 14 of the
selection experiment. These are referred to as Evolved Black/6 and Evolved SCID mice.
Tumor volumes were measured with a caliper twice weekly up to 18 days. Tumors were
collected from five of the animals at 11 days, and the remaining tumors were collected
at 28 days.
Cell Culture and inoculation
LL/2-luc-M38 are a bioluminescent cell line of Lewis Lung carcinoma cells, which
were derived from a spontaneous lung tumor in C57BL/6 mice. We obtained these cell
lines from Xenogen Corporation (Alameda CA)). Cells were authenticated by short
tandem repeat analysis and confirmed to be free of mycoplasma. The LL/2-luc-M38
cells were grown in DMEM/F12 supplemented with 10% fetal bovine serum (HyClone)
and 1% pen strep (Corning) in 5% CO2. To be certain the observed effects were due to
host evolution and not tumor cell evolution, we expanded the original LL/2-luc-M38 cells
through in vitro cell culture prior to the experiments, divided this population into aliquots
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of 5x10^5 cells in 200µL PBS and stored them at -80°C. For injections, the hair was
removed from the right flank of each mouse and the 200µl cell suspension from these
aliquots was slowly injected with a 27G needle.
For the experimental metastasis model, 200 µL containing 5 x 10^5 cells in PBS
were injected directly and slowly (over the course of 1 minute) into the tail vein of each
mouse and cell distributions were verified by bioluminescent imaging immediately
following injection.
Bioluminescent Imaging
In vivo bioluminescence imaging was completed with the Xenogen IVIS-200
System (Caliper Life Sciences, Hopkinton, MA) as previously published(Robey et al.
2009). Prior to each IVIS imaging session, mice were intraperitoneally injected with
sterile d-luciferin at 10µl per gram body weight. D-luciferin was prepared in PBS at
15mg/ml. After tumor injection, the mice were placed inside of an oxygen rich induction
chamber consisting of 2.5% Isoflurane (Henry Schein, Melville, NY). The mice were
then imaged 5 minutes post injection. Mice were placed on their left side on the
imaging platform. Anesthesia was maintained using nose cones with a 1.5-2%
isoflurane flow rate. The IVIS imaging chamber consists of a warming platform and a
cryogenically cooled CCD camera to capture both a visible light photograph of the
animals and a bioluminescent image. Data was acquired and analyzed utilizing the
Living Imaging 4.3.1 software. Regions of interest were placed around each tumor to
assess the photon intensity, in units of photons/second (p/s).
Tumor cell isolation
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Tumors were collected from mice post-mortem and placed in cold DMEM with
5% penicillin streptomycin. Tumors were processed immediately after resection by
mechanical dis-aggregation. Tumor tissues were placed in sterile 10cm culture dishes,
washed in DPBS, and excess tissue including adipose and skin were removed. Tumors
were minced into 2-3 mm fragments and placed in a sterile tissue sieve with 44mm
nylon mesh. DMEM with 10% FBS was added and the tissues were dis-aggregated by
mechanical pressure using the sterile blunt end of a syringe handle. The resulting single
cell suspension was cultured at 37°C with 5% CO2. Media was changed daily and cells
were frozen after 2-3 passages in FBS with 10% DMSO. For microarray analyses, cells
were later thawed and passaged 3 times prior to RNA isolation for microarray analyses.
Splenocyte Survival and Tumor Cell Killing Assay
Spleens were removed from mice postmortem and placed in 5 ml RPMI-1640
containing 10% penn/strep in 15 ml conical tubes and transported on ice. Spleens were
then placed in 10 cm Petri dishes and washed with phosphate buffer saline (PBS).
Mechanical disaggregation was performed using 100-micron mesh and a syringe piston.
Tissues were washed with PBS and filtered through a 70 micron filter to achieve a
single cell suspension and centrifuged at 1500 RPM for 5 minutes. To remove red blood
cells, pellets were resuspended in 15 ml ACK (ammonium-chloride-potassium) lysing
buffer (ThermoFisher Scientific) for 15 minutes with intermittent agitation. Thirty
milliliters of RPMI-1640 containing 10% fetal bovine serum was added and cells were
spun down to remove lysis buffer. Following two washes with 10 ml RPMI-1640,
splenocytes were counted and rested for 2 hours in RPMI-1640 containing 10% fetal
bovine serum at 37° C with 5% CO2.
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LL/2-luc-M38 cells were thawed and passaged twice. After removal from the flask
with 0.5% Trypsin-EDTA cells were washed in RPMI-1640 with 10% FBS and counted.
Cells were fluorescently labeled with 1 µM CellTrace Violet (Thermo Fisher) in PBS at a
concentration of 1x10^6 cells per ml for 20 minutes at 37° C. RPMI-1640 with 10% FBS
was added for 5 minutes to remove any free dye. Cells were then washed and counted.
Unstained splenocytes and fluorescently labeled LL/2-luc-M38 cells were cocultured at a 20:1 effector to target cell ratio for 24 hours. Suspension and adherent
cells were collected and counted. Additionally, cells were stained with propidium iodide
(PI) and analyzed by flow cytometry (BD LSR II, BD Bioscience). Splenocyte cell
number was determined by multiplying the frequency of PI negative, CellTrace Violet
negative cells by the total live cells counted. Tumor cell number was calculated by
multiplying the frequency of PI negative, CellTrace Violet positive cells by total live cells
counted. Percent killing was calculated as [(untreated - treated)/untreated] x 100
(Supplemental figure 8).
Complete Blood Counts (CBC)
CBC was performed following standard protocols. Blood was collected
postmortem from non-tumor bearing mice via cardiac puncture. This terminal collection
was completed by laying the animal on its back and inserting the syringe vertically
through the sternum. Approximately 300-350 µl was collected and placed into an EDTA
tube. Analysis was performed using a Heska HemaTrueTM analyzer.
Immune Panel on Peripheral blood
Blood was collected postmortem via cardiac puncture. Red blood cells were
lysed in 15 ml ACK lysing buffer (ThermoFisher Scientific) for 15 minutes with
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intermittent agitation. 30ml of RPMI-1640 containing 10% fetal bovine serum was added
and cells were spun down to remove lysis buffer. Remaining cells were stained in PBS
containing 0.5% BSA and 0.1% sodium azide with Ly-6G/C FITC, NK1.1 APC, CD3e
APC-Cy7, and CD19 V450 for 1 hour at 4°C. Samples were analyzed using BD LSR II
flow cytometer with Diva acquisition software. FlowJo (Treestar) analysis software was
used with standard gating practices to remove debris and doublets.
Immunohistochemistry
Tissue slides were stained using a Ventana Discovery XT automated system
(Ventana Medical Systems, Tucson, AZ) as per manufacturer's protocol with proprietary
reagents. Slides were deparaffinized on the automated system with EZ Cell
Conditioning 1 (Ventana). The detection system used was the Ventana OmniMap kit.
Slides were then counterstained with Hematoxylin. Next, the slides were dehydrated
and cover slipped as per normal laboratory protocol. The rabbit primary antibody that
reacts with mouse CD31, (#ab28364, Abcam, Cambridge, MA) was used at a 1:200
concentration in Dako antibody diluent (Carpenteria, CA) and incubated for 32 minutes.
The Ventana Anti-Rabbit Secondary Antibody was used for 20 minutes. The rabbit
primary antibody that reacts with mouse Cleaved Caspase 3, (#9661, Cell Signaling,
Danvers, MA) was used at 1:2000 concentration in Dako antibody diluent and incubated
for 60 minutes. The Ventana Anti-Rabbit Secondary Antibody was used for 16 minutes.
The rabbit primary antibody that reacts with mouse Ki67, (M3060, Spring Biosciences,
and Pleasanton, CA) was used at a 1:100 concentration in Dako antibody diluent and
incubated for 32 minutes. The Ventana OmniMap Anti-Rabbit Secondary Antibody was
used for 20 minutes.
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Image analysis
An Aperio (Vista, CA) Positive Pixel Count® v9.0 algorithm software with the
following thresholds: [Hue Value =.1; Hue Width =.5; Color Saturation Threshold =0.04;
IWP(High) = 220; Iwp(Low)=Ip(High)=175; Ip(low) =Isp(High) =100 Isp(Low) =0] was
used to segment positive staining of various intensities. The algorithm was applied to
the entire digital core image to determine the percentage of positive biomarker staining
by applicable area. The percentage of positive pixels (sum of weakly positive, positive,
and strongly positive divided by total pixels) in the applicable viable tumor area
(designated by excluding necrotic volumes identified on H&E images) was then
calculated.
Second harmonic generation imaging
Second Harmonic Generation (SHG) images were captured through a
25X/0.95NA water objective lens with a Leica SP5 Multiphoton Microscope (Leica
Microsystem GmbH, Wetzlar, Germany) equipped with a MaiTai DeepSee Ti-sapphire
laser (Spectra-Physics Inc., Mountain View, CA) and HyD detectors. The MP laser was
tuned to 880 nm and emissions were collected through a 440nm band pass filter in
order to achieve SHG imaging. In addition to SHG, bright field images of the identical
fields were captured using an Argon laser tuned to 488 nm and transmitted light PMT.
All images and overlays were prepared in Leica LASAF software (Leica Microsystems
GmbH, Wetzlar, Germany). Using Definiens Developer version 2.4 (Definiens AG,
Munich, Germany), SHG signals from each image were evaluated. ROI was drawn at
the edge and the core of the tissue along the observed interface of differential tissue
morphology. An auto-threshold algorithm was used to segment the SHG signal from
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the background within the edge and the core regions. Then total fluorescence signal
from SHG was determined for each region in each image. Finally, SHG signal per tissue
area was calculated by using the bright field image to determine total area of the region.
Isolation of RNA and sample processing for microarray analysis
Total RNA from mouse tumors and cells was isolated and purified using the
RNeasy cleanup procedure (Qiagen Inc., Valencia, CA). The quality of total RNA was
assessed by agarose gel electrophoresis and A260/A280 ratio using the NanoDrop
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). One hundred nanograms
of total RNA served as the mRNA source for microarray analysis. The poly (A) RNA was
converted to cDNA and then amplified and labeled with biotin using the Ambion
Message Amp Premier RNA Amplification Kit (Life Technologies, Grand Island, NY)
following the manufacturer’s protocol initially described by Van Gelder et al(Van Gelder
et al. 1990). Hybridization with the biotin-labeled RNA, staining, and scanning of the
chips followed the procedure prescribed in the Affymetrix technical manual (Affymetrix,
Santa Clara, California, USA). Scanned output files were processed using Affymetrix
Expression Console software. The RNA isolation and microarray processing were
performed by the Molecular Genomics Core at the Moffitt Cancer Center.
Probe arrays
We used the GeneChip® Mouse Genome 430 2.0 Array to measure gene
expression in the LL/2-Luc-M38 tumors. This array contains over 45,000 probe sets
designed from GenBank, dbEST, and RefSeq sequences that were clustered based on
build 107 of the UniGene database. The clusters were further refined by comparison to
the publicly available draft assembly of the mouse genome. An estimated 39,000
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distinct transcripts were detected including over 34,000 well substantiated mouse
genes. Each gene is represented by a series of oligonucleotide probes that are
identical to the sequence in the gene (PM probe) as well as oligonucleotides that
contain a homomeric (base transversion) mismatch at the central base position of the
oligomer (MM probe); this measures cross-hybridization.
Microarray analysis
Quality control of arrays was made by generating the following plots: PCA,
NUSE, RLE, Density, Intensity and RNA degradation, and analysis was done with inhouse R(3.1.1) scripts. Data were normalized using Robust Multi-array Average (RMA)
algorithm. One outlier sample was defined in PCA plots as a sample that did not
clustered together with the rest of the replicate samples. Instead, the outlier sample was
clustered into another group. Only samples that passed all filters were selected for
further analysis. Principle component analysis (PCA) was performed using Evince
V2.7.0 (UmBio AB, Umeå, Sweden).
On the normalized and filtered data, we used principal variance components
analyses [PVCA; 13-15] in JMP/Genomics (Version 8 for Windows; SAS Institute, Cary,
NC, USA) to examine global expression trends in the LL/2-Luc-M38 tumors that were
associated with host accession and level of host selection. The PVCA approach first
reduces the dimensionality of the data set with PCA, and then computes variance
components by fitting a mixed linear model to each principal component, treating each
factor of interest in the model as a random effect (including continuous variables). We
used the model PCi = accession + selection level+ accession-by-selection level+ error,
where i indicates each principal component, starting with 1 and continuing through all
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principal components calculated in the PCA. The variance component for each factor is
obtained by a weighted averaging across the values calculated for each principal
component, weighted by the eigenvalues for the corresponding principal component.
We used the same factors in a mixed model ANOVA to directly fit the model to gene
expression (ANOVA model: gene expression = accession + selection level + accessionby selection level + error).
To identify the probsets that can differentiate Non-evolved SCID from EvolvedSCID at 11 days, we initially made PCA plots with all probsets. Then, select those
probsets whose absolute loading values is greater than 0.02. In the final PCA plots, the
first component captured 89.9% of variance and the second 7.18%. We made
heatmaps based on the expression values of the selected probesets. To get log2 fold
change between Non-evolved SCID and Evolved SCID, we used the average values of
Non-evolved SCID and Evolved SCID groups: log2fc = average (log2NESD) – average
(log2ESD). The probesets were split into up- (>0.5850 0) and down-regulated (<0.5850) groups according to the log2fc value (i.e. a minimum 1.5X fold change).
Probesets were annotated with Mouse430_2.na36.annot.csv (create date 03-30-2016).
We further analyzed up and down regulated genes with MetaCore™ (Bioinformatics
software from Thomson Reuters, https://portal.genego.com/) for significant pathway
analysis and GO TERM enrichment analysis.
Quantitative Real Time PCR
All qRT-PCRs were performed on a 7900HT Fast-Real-Time System (Life
Technologies Applied Biosystems®) using an iScript Real-Rime PCR kit with SYBR
Green (BioRad, 170-8893). GAPDH expression was used as an internal control. Using
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RNeasy Plus Mini Kit (Qiagen), RNA was isolated from cancer cells isolated from the
primary tumors of Non-evolved -SCID -11days and Evolved-SCID-11days. 100 ng of
mRNA was used per 20 µL reaction. The mRNA expression levels were normalized by
calculating the ratios against GAPDH expression levels. Primers for Collagen 12a1
(Col12a1) F-5′-ACCCACCTTCCGACTTGAATT-3′,R- 5′TAGGCCCATCTGTTGTAGGG-3′ were obtained from integrated DNA Technologies
(Coralville, IA)38
Quantification of lung metastasis volume with MRI
Ex-vivo images of lungs from Non-evolved and Evolved mice were obtained
using T2-weighted pulse sequence in a 7 Tesla Biospec (Bruker Biospin Inc.). A 35 mm
Litzcage coil (Doty Scientific) was used to carry out axial T2-weighted fast spin-echo
multislice experiments (acquired with TE/TR [echo time/repetition time] = 31 ms/1700
ms, field of view (FOV) = 20 × 20 mm2, matrix = 256 × 256, yielding a spatial in-plane
resolution of 78 µm, slice thickness of 0.5 mm). Tissue slices covered all of the tissue,
and there were no gaps between sequential slices. Images were quantified by drawing
ROIs manually and using an implemented home-made code in AEDES software
(Aedes, http://aedes.uef.fi/).
Statistical analysis of tumor growth
We used ANCOVA (SYSTAT v13) to compare the effects of mouse accession
and generation on tumor growth. In separate analyses, we used tumor size at week 7
(logarithmically transformed) and at week 14 (also log transformed) as the dependent
variable. As independent variables, mouse accession was a categorical variable and
mouse generation was a covariate. If slopes were homogeneous across groups (non-
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significant interaction of mouse accession and generation at p > 0.1) then the analysis
was rerun without the interaction effect. This was the case for tumor size at week 7 but
not so for tumor size at week 14. So, we ran separate least squares regressions
(SYSTAT v13) of generations of selection on week 14 log tumor sizes for the SCID and
Black/6 mice. For additional tests of means, we used Student’s t-tests where a p-value
of < 0.05 was considered statistically significant (Prism 5 software

Results
The Mice evolved
Here we applied artificial selection to immunocompetent (C57BL/6, also named
Black/6) and immune-deficient (SCID) mice to investigate evolutionarily available cancer
suppression strategies. We injected Lewis lung carcinoma cells (LL/2-Luc-M38) freshly
prepared from frozen stocks subcutaneously into 6-week old male mice. The two
recipient mice with the slowest tumor growth were then bred with females from the
same generation (Figure 4.1A and B) and male mice from these litters were
subsequently inoculated with LL/2 cells. Each cycle required 2.5-3.0 months to
complete. Final tumor sizes were larger in the SCID mice than in immunocompetent
Black/6 mice (F1,195 = 9.62, p < 0.002). We observed rapid evolution of increased
resistance to tumor growth in both mouse accessions. Artificial selection over 10
generations resulted in a significant reduction of tumor size at day 7 (F1,195 = 17.16, p <
0.001). However, tumor growth in Evolved Black/6 mice accelerated after day 7 so that
the tumor size at day 11 was not significantly different from control (slope of -0.092, t90 =
0.44, adjusted r2 = 0.013) (Figure 4.1. C and D).
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In contrast, tumor suppression persisted in the SCID mice through day 11 and
this growth inhibition increased with each generation (slope of -0.847, t104 = 5.5,
adjusted r2 = 0.255). To examine the durability of the host strategy for tumor
suppression, we measured the tumor beyond the usual selection date (i.e. day 11).
During this period, tumor growth in the Evolved mice accelerated and was not different
in size from the control group (i.e. Non-evolved mice) (Figure 4.2A and B).
Altered host responses in the evolved mice
Under artificial selection pressure, both mouse accessions evolved enhanced
mechanisms of tumor suppression. Evolved immunocompetent Black/6 mice
demonstrated increased immune responses to the LL/2-Luc-M38 cells, while the
evolved immune-deficient SCID mice increased biomechanical suppression of tumor
growth through fibrous encapsulation.
Black/6 mice have intact innate and adaptive immune systems. Therefore,
Evolved Black/6 mice were examined for changes in immune cell frequency, phenotype,
and function. Complete blood counts, flow cytometric immune-phenotyping, and ex vivo
functional assays were performed comparing Non-evolved and Evolved Black/6 mice.
Prior to tumor injection, Evolved and Non-evolved Black/6 mice did not differ in
monocyte counts. However, five days post injection and at end of the study (28 days),
circulating monocytes were significantly lower in the Evolved than Non-evolved Black/6
mice (p=0.0036 and p=0.04 respectively) (Figure 4.3 A). Survival and killing capacity of
splenocytes isolated from tumor-resistant Evolved Black/6 mice were significantly higher than
Non-evolved mice (p=0.0001, and p=0.003 respectively) (Figure 4.3 B - E). No significant

changes in circulating white blood cells counts, lymphocyte counts, or granulocyte
counts could be detected during tumor growth (Figure 4.4 A-C). There were no
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changes in NK1.1+, CD19+, or Gr1+ cells detectable by flow cytometry. However,
circulating CD3e+ T cells were significantly lower (p=0.0172) in the Evolved Black/6
mice than in the Non-evolved mice at the end of the study (Figure 4.4 D-G).
In contrast to Black/6 mice, Severe Combined Immunodeficiency (SCID) mice
cannot mount an adaptive immune response thus limiting their options for restricting
tumor growth to innate macrophage and neutrophil-mediated immunity (Figure 4.5 A,
B). The killing capacity of splenocytes isolated from Non-evolved and Evolved SCID
mice did not differ significantly (Figure 4.6 A and B). Immune-deficient SCID mice were
observed to suppress tumor growth via mechanical restriction with increased collagen
deposition in and around the tumor. We found collagen content in the stroma
surrounding 11-day old tumors to be significantly higher (p=0.0158) in the Evolved
tumor-resistant SCID mice than in the Non-evolved mice To examine the durability of
the host strategy for tumor suppression, collagen deposition was quantified beyond 11
days, and no increase in collagen deposition in Evolved tumor –resistance mice was
observed (Figure 4.7 A and B). Collagen was significantly increased at the tumor
injection site as well as in the opposite (un-injected) flank (p=0.025) in the nontumor
baring Evolved SCID mice (Figure 4.7 C and D). Encapsulation or walling off injured
and infected tissues is a host defense strategy to isolate and suppress pathogen growth
in organisms lacking adaptive immune responses including lower invertebrates and
many plant species (D. 1997; Lemaitre and Hoffmann 2007). Furthermore, tumor
encapsulation (Jackson and Byrne 2002; Barr 1989) and fibroblast infiltration(Pandol et
al. 2009) (desmoplasia) is frequently observed clinically.

106

Tumor Cell Counter Strategies
Having shown that artificial selection promotes the evolution of host tumor
suppression during the experimental period, we then investigated the durability of this
response. Does the evolved host tumor suppression persist, or do the cancer cells
evolve counter strategies? We therefore investigated the phenotypes of LL/2 tumor
cells that were grown as tumors in Evolved or Non-evolved Black/6 or SCID mice using
immunohistochemistry and microarray analysis.
The Evolved Black/6 mice demonstrated peak tumor suppression (tumor growth
compared to that of Non-evolved mice) at day 7. By day 11, the tumor size of LL/2-LucM38 cancer cells in the Evolved mice rapidly approached the tumor size in the Nonevolved mice.. The LL/2-Luc-M38 cells growing in the Evolved Black/6 mice displayed
two adaptive strategies – faster proliferation (Figure 4.8 A and B), and decreased
angiogenesis (Figure 4.8 C and D) compared to the parental cell line growing in Nonevolved Black/6 mice.
On the other hand, in the Evolved SCID mice, LL/2-Luc-M38 cells displayed
lower cell proliferation and higher necrosis as a response to mechanical pressures by
collagen (Figure 4.9 A - C). No difference in angiogenesis was observed (Figure 4.10A
- C).
We also examined changes in gene expression patterns from the tumors
extracted from Non-evolved and Evolved Black/6 and Non-evolved and Evolved SCID
mice at the end of the study (day 28 of tumor growth)(Li J 2009; Richards et al. 2012;
Alvarez et al. 2018). With a general linear model, we examined how much of the
variance in gene expression of the tumors was explained by the host accession (SCID
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vs Black/6) that the tumors were grown in, the level of selection the host had
experienced (Non-evolved vs Evolved), or the interaction of how tumors from different
host accessions responded differently to host selection. Principal component 1 (PC1)
explained 35% of the variation in genome-wide gene expression and was most closely
associated with the interaction term (accession x level of host selection) in the model. In
addition, the majority of transcriptional variance was attributed to the interaction
between host accession and host level of selection (35.6%) followed by differences
explained by host accession (19.4%), and difference explained by levels of host
selection (14.8%) The tumors from the two mouse accessions differed significantly in
expression of 615 genes, tumors in the two levels of selection differed in expression of
335 genes, while the interaction term explained a significant amount of variation in 1215
genes. These results support the hypothesis that the different mouse accessions
elicited different responses in the tumors and that the tumors response to selection for
resistance in the host also depended on the host accession (Figure 4.11 A and B).
We further explored genes that were differentially expressed between tumors
grown in Non-evolved Black/6 and Evolved Black/6 mice (Figure 4.12 A). When
classified by function, the differentially expressed genes were enriched for
developmental processes, cell migration and movement, as well as cell membrane
composition (Figure 4.12 B). The gene with the highest fold expression increase was
Semaphorin 3D (Sema3D), which is implicated in the development and formation of
blood vessels during angiogenesis, and the regulation of the epithelial to mesenchymal
transition, EMT (Worzfeld and Offermanns 2014; Tseng et al. 2011; Foley et al. 2015)
(Figure 4.12 C).
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In the SCID mice, the greatest difference in tumor size between Non-evolved and
Evolved mice occurred at day 11. From day 11 to day 14, we saw accelerated tumor
growth in the Evolved SCID mice, and after day 14, the tumor sizes of Non-evolved and
Evolved mice did not differ significantly, indicating that the LL/2-Luc-M38 cells had
counteracted the enhanced anti-tumor strategies of the Evolved SCID mouse. The LL/2Luc-M38 cells in the Evolved SCID mice appeared to eventually disrupt the increased
density of extracellular matrix. We identified gene expression differences in cancer cells
harvested at day 11 (Figure 4.13A). Most genes with increased expression in the
evolved SCID mice were related to integrin binding, cell adhesion molecular binding,
and extracellular matrix (ECM) binding (Figure 4.13 B). Expression levels of
extracellular matrix markers such as collagen type VI (Col18a1), alpha, prolyl 3hydroxylase 2 (p3h2), and collagen, type XII alpha (Col12a1) were decreased in the
cells isolated from Evolved mice compared to Non-evolved (Figure 4.13.C). Validation
of Col12a1RT-PCR expression levels demonstrated a significant decrease (**p=0.009)
in Col12a1 as expected (Figure 4.13 D). other genes were not validated since it is
beyond the scope of this paper.
Tail vein injections of Lewis lung cell line in both Non-evolved and evolved SCID
mice, demonstrated no development of resistance to metastasis, indicating that the
resistance was specific to the subcutaneous model (Figure 4.14 A – D).

Discussion
Here we selectively bred laboratory mice to promote adaptations rendering them
relatively resistant to a cancer cell population. One of our goals was to determine

109

feasibility – could we evolve, by selective breeding, resistance in laboratory animals
within a reasonably short period of time and using a relatively small number of animals?
Within 10 generations two mouse accessions (the immune-competent Black/6 and the
immuno-deficient SCID) evolved tumor suppressor adaptations to Lewis Lung cancer
cell tumors. Such experiments could be repeated using different hosts and different
tumor types to demonstrate the range of tumor resistance strategies available in
multicellular organisms. With the mice evolving resistance, we anticipated that the
cancer cells would deploy observable counter-adaptations in response to the hosts’
cancer suppression mechanisms. This evolutionary tumor-host “arms race” where hosts
evolve over generations and cancer cells evolve within hosts has been anticipated
theoretically, but not experimentally investigated systematically(Arnal et al. 2015).
The early suppression of tumor growth in the Evolved Black/6 mice depended on
changes to the innate immune system, more so than we anticipated. Furthermore,
contrary to expectation, molecular studies of tumor cells’ counter measures did not
show significant changes in the expression of immune-related genes. Rather we found
decreased expression of genes associated with angiogenesis, and ATP production (and
the proliferation rate), as well as increased expression of genes regulating EMT. Note
that these cancer cell counter measures did not necessarily require novel mutations
(although we did not evaluate possible sequence differences). Rather, the tumor
population deployed adaptive strategies involving changes to the intrinsic properties of
individual cells, and a more global change in the vascular ecology of their tumor
microenvironment (Ibrahim-Hashim et al. 2017; Damgaci et al. 2018a). Collectively,
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these changes would impede the target immune response of the mouse to access the
cancer cells.
Increased fitness is a common adaptation of prey following introduction of a
predator – simply proliferating faster than the predator can kill them. Hence, the LL/2Luc-M38 cells may have increased fitness as a rapid response to the heightened
predatory activity of the immune response in the Evolved Black/6 mice. Reduced
angiogenic signaling in the LL/2 cells grown in evolved Black/6 mice by day 11
compared to tumors in Non-evolved mice (p = 0.0148) was likely a “niche construction”
strategy. Although quantification of tumor infiltrating immune cells was not included in
our analysis, reduced blood flow may be represent an immune evasion strategy by
tumor cells. Reduced vasculature provides cancer cells with safety through decreased
immune cell delivery and reduced efficiency of immune-cell attack due to associated
hypoxic and acidic environmental conditions (Ibrahim-Hashim A 2017).
In contrast, the immune-deficient SCID mice, reduced tumor growth by
increasing mesenchymal cell proliferation. This host strategy may restrict tumor growth
via barriers and space limitations and suppress cancer cell proliferation as the rapidly
growing mesenchymal population competes for space and nutrients. The molecular
counter measures in the LL/2-Luc-M38 cells to the host defense manifested as
increased expression of genes that produce remodeling of the extracellular matrix. This
suggests that the host defense was primarily one of biomechanical restriction and the
cancer cells upregulated the means to degrade the barriers (Figure 14.15). While
mesenchymal infiltration and fibrosis is commonly observed in desmoplastic clinical
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cancers, the role of biomechanical tumor suppression is relatively under-appreciated
compared to that of the immune system.
In conclusion, a growing tumor represents one of many possible outcomes from
the complex eco-evolutionary interactions between cancer cells and their host
organism. The role of the host in tumor suppression is well-recognized. Studies have
addressed the unexpectedly low cancer rates in large (e.g. whales and elephants) or
long-lived (e.g. naked mole rats) animals found in nature (Valerie K. Harris 2017).
Laboratory mice entirely resistant to injected cancer cells have been serendipitously
discovered (Cui et al. 2003). Here, we took short lived mice that ordinarily would have
little need for tumor suppression. We gave them that need by inoculating them with a
rapidly growing, lethal cancer cell line. Eleven days following injection of cancer cells
into Evolved mice, we saw reduced tumor growth. The Evolved mice appeared more
vital and healthy compared to the non-evolved mice . We saw each host accession
evolve mechanisms to suppress tumor growth to 7-11 days, but not after that.
Countering these host responses is the evolutionary dynamics of cancer cells.
Since cancer populations die with their host, each new tumor must re-evolve solutions
to the inherited defenses of the host. This would seem to be a significant disadvantage
for the cancer cells. However, the cancer cells possess the same genome as the host.
Thus, every anti-tumor strategy in the host will likely have an antidote encoded in the
genome to prevent damage to normal cells. In our study, the tumor cells were from the
same species though not the same accession as the host but nevertheless the tumors
could rapidly “find” solutions to the host response within their genome.
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Finally, we demonstrate that rapid and profound evolution in cancer populations
could result from changing gene expression, which could result from simply accessing
information already encoded in the genome of the host species. The causal genomic
mechanisms underlying these expression changes remains to be discovered.
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Figures

Figure 4.1 Experimental design for selection of Evolved mice, and tumor growth. A Evolved
Black/6 (n = 10, male). B Evolved SCID mice (n = 10, male). C Comparison of tumor growth in
Non-evolved Black/6 mice (n = 5) and in Evolved Black/6 mice (n = 5). D Comparison of tumor
growth in Non-evolved SCID mice (n = 5) and in Evolved SCID mice (n = 5). There was a
significant difference in the tumor growth starting at 3 days post injection of Non-evolved and
Evolved Black/6 mice (*p = 0.01) but not after 7 days. There was a significant difference in
tumor growth at 11 days post injection of Non-Evolved and Evolved SCID mice (***p = 0.001),
but not at 15 days. Mean+/- SEM is plotted with significance based on two-tailed unpaired
Student’s t-test.
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Figure 4.2 Quantification of tumor bioluminescent over time for generations 1 to 10 in: A SCID
mice and B in Black/6. Both accessions demonstrate a significant decrease starting at 7 days
post-inoculation and at 4th generation (p<0.001 in both cases). Mean+/- SEM (n=10) is plotted
with significance based on ANCOVA (analysis of covariance). Note log scale.
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Figure 4.3 Strategy of Evolved Black/6 mice A Monocytes count in Non-evolved and Evolved
Black/6 demonstrating a significant decrease in Evolved mice at day 5 and at the end of the
study (p<0.04). B, C Ex-vivo tumor cell killing assays demonstrated a significant increase in the
number of surviving splenocytes (p=0.0001), and higher percent of tumor cell death in Evolved
Black/6 mice compared to Non-evolved (p=0.003). D Gating strategy for splenocytes survival
and functional assays. E Representative image of functional assay, fluorescently labeled
Splenocytes cultured with tumor cells are showed in pink arrows, and tumor cells showed in
green arrows.
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Figure 4.4 Immune cells counts in blood: Quantification of A White blood cell count, B
Lymphocytes counts, and C granulocytes counts between Evolved mice and Non-evolved
Black/6 mice, no differences are observed in white blood and lymphocytes counts, however,
significant decrease in baseline in Evolved compared to Non-evolved ( p=0.003) is observed.
Frequency of D NK cells (CD3-,NK1.1+) E B cells (CD3-, NK1.1- CD19+) F T cells (NK1.1-,
CD3e+) and G Gr1+ cells performed by flow cytometry demonstrated no change in NK1.1+,
CD19+ or Gr1+ cells between the Non-evolved and Evolved Black/6 mice. T cells were slightly
decreased (p=0.0172) in the Evolved mice after 25 days of tumor growth.
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Figure 4.5 Immune cell frequencies in Non-evolved Black/6 and SCID mice: A Black mice have
an intact lymphocyte compartment. B SCID mice have decreased white blood cell counts and c
lymphocyte counts compared to Black/6 mice (p<0.0001 and p<0.001 respectively).
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Figure 4.6 A Ex-vivo quantification of surviving splenocytes, and B tumor cell killing assays
demonstrated no differences between Non-evolved and Evolved SCID mice. Mean+/- SEM is
plotted with significance based on two-tailed unpaired t -test was employed
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Figure 4.7 Strategy of Evolved SCID mice A Representative images of tumor collagen
fibrillary structure in Non-evolved and Evolved SCID at 11days and at 28 days post tumor
inoculation. On the top of each image is a schematic presentation of the model showing the
acclimation of the tumor cells to the increased collagen at early time point of Evolved SCID
mice. B Quantitative analysis of the tumor collagen in Non-evolved and Evolved SCID at 11days
and 28 days, showing significant differences at 11 days between Non-evolved and Evolved
(p=0.0158), between 11 and 28 days of Non-evolved (p=0.03), and between 11 and 28 days of
Evolved (p=0.0001).C Representative images of skin collagen fibrillary structure in Non-evolved
and Evolved SCID at the injection site and Evolved non-injection site D Quantitative analysis of
the skin collagen showing a significant increase (*p=0.025) between Evolved and Non-evolved
mice on the injected sites. Mean+/- SEM is plotted with significance based on two-tailed
unpaired t-test.
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Figure 4.8 Counterstrategy of tumor cells at 11 days post injection into Black/6 mice. A
Immunohistochemistry staining and B quantification of Ki67 (n = 5). Representative images of
the tumor (upper panel) as well as a positive mask (lower panel). Percent Ki67positive pixels
were quantified over the entire viable area of tumor cross-section. Mean+/- SEM is plotted. C
Representative images of immunohistochemical staining of Evolved and Non-evolved Black/6
tumor tissue. Scale bar in IHC images is 200µm. Quantification of D total number of vessels
and E micro vessel density (MVD) across the whole image demonstrating significant decreased
of total number of vessels (*p= 0.0139 ) and number of vessels per unit area (*p= 0.0148) in
Evolved compared to Non-evolved black/6 mice. Mean+/- SEM is plotted with significance
based on two-tailed unpaired Student’s t-test.
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Figure 4.9 Tumor cell proliferation and necrosis at day 11, A Immunohistochemistry staining
and B quantification of Ki67 in tumors in Evolved SCID mice. Representative images of the
tumor (upper panel) as well as a positive mask (lower panel). Percent Ki67 positive pixels were
quantified over the entire viable area of tumor cross-section. Mean+/- SEM is plotted. Scale bar
in IHC images is 200µm. C Percent necrosis of tumor cells in Non-evolved SCID mice and
Evolved SCID mice. Mean+/- SEM is plotted.
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Figure 4.10 Angiogenesis: Microvessels in tumors at day 11. A Quantification of mean
vessel perimeter in tumors of Non-evolved Black/6 mice and in Evolved Black/6 mice. There
was no significant difference. B, C Quantification of microvessel density (MVD), and mean
vessel perimeter for Non-evolved SCID mice and Evolved SCID mice. There was no significant
difference. Mean +/- SEM are shown with significance based on two-tailed t-test.
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Figure 4.11 Components of transcriptional variance in tumor cells, A percent of the
transcriptional variance in tumors explained by which host accession (SCID vs Black/6) was
infected, the level of host selection (Non-evolved vs Evolved) and the interaction of tumors from
the two host accessions and the level of host selection (Accession x Selection).B number of
genes that significantly differ between tumors from Black/6 and SCID accessions, tumors from
Evolved vs Non-evolved mice (selection status), and that show an accession-by-selection status
interaction
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Figure 4.12 Counterstrategy of tumor cells in Evolved Black/6 mice at 28 days.
A Heat map analysis of tumor isolated from Non-evolved and Evolved Black/6 mice at 28 days.
Two replicates of each are shown (green=downregulated genes and red=upregulated genes),
normalized expression value is indicated at the top of the figure. B Gene ontology enrichment
analysis of microarray data between Non-evolved and Evolved Black/6 (Top 15 processes),
processes that have the same function were grouped together and color coded. C The
Expression level of genes related to angiogenesis angiopoietin 1 (Angpt1) and semaphorin-3
(Sema3 f, c and d subtypes) (n=2). NEV (Non-evolved), EV (Evolved).
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Fig. 4. 13 Counterstrategy of tumor cells at 11 days post injection into SCID mice. A Heat
map of genes differentially expressed between Non-evolved and Evolved SCID mice at early
(11Days) time point. B Gene ontology enrichment analysis of microarray data between Evolved
and Non-evolved SCID at 11 days (Top 15 processes). C Expression level of genes related to
extracellular matrix pathways in Evolved SCID mice compared to Non-evolved -SCID mice
(n=3). Genes are collagen subtypes (12a, 6a3, and 18a1) and poly3-hydroxylase (P3h2).
Details about regulated genes are available in the online supplements as well as raw data files.
D QRT-PCR showing significantly (p=0.009) decreased expression of Col12a1in Evolved SCID
mice (n=3). Mean+/- SEM is plotted. A 2 tailed unpaired Student’s t-test was employed. NEV
(Non-evolved), EV (Evolved).
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Figure 4.14 No experimental metastasis. - A. Mean tumor bioluminescence in Non-evolved
and Evolved SCID mice (n=5) after induction of experimental metastases, indicating no
difference in metastases in the Non-evolved -SCID cohort than in the Evolved SCID mice (note
log scale). B MRI (Top) and H&E images (middle and lower) Images of the lung for one
representative mouse from each group. C Total lung metastasis volume measured by MRI, and
D Percent lung metastasis quantification of H&E. Mean+/- SEM is plotted. A two-tailed unpaired
Student’s t-test was employed.
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Figure 4. 15 Model of tumor growth in Evolved SCID mice versus Non-evolved SCID mice,
showing the acclimation of the tumor cells to increased collagen at early time point of evolved
mice by decreasing the integrin binding collagen XIIa1.
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CHAPTER 5
THE MOLECULAR BASIS OF CANCER ADAPTATION IN AN EVOLUTIONARY
ARMS RACE WITH THE HOST

Abstract
Background: Genetic and nongenetic changes can drive abnormal characteristics
of cancer cells, including resistance to tumor growth. Through selective breeding, we
evolved resistance to tumor growth in two contrasting accessions of mice: severe
combined immunodeficiency disease (SCID) and immuno-competent C57BL/6 (black).
We found that the two accessions evolved different strategies that allowed for
resistance. Skin fibroblasts mediated the evolved resistance in immunodeficient mice,
while the immune-mediated killing of cancer cells facilitated the evolved resistance in
immunocompetent mice. We aimed to discover the molecular level mechanisms
underlying these resistance traits.
Results: For each accession, we aimed to identify transcriptomic changes in
response to time and selection in both skin and tumor samples. In both accessions,
more genes were upregulated or downregulated in response to time than in response to
selection. Over time, SCID mice downregulated genes involved in extracellular matrix
(ECM) remodeling proteins, and genes involved in metabolic pathways in skin, while
SCID tumors upregulated the expression of ECM disrupting proteins. However, in
response to selection, SCID mice upregulated genes that are affiliated with the miRNA
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class in skin, and tumor cells upregulated genes involved in the ECM remodeling
pathway. In pair wise comparison between SCID skin and tumor samples, at 11 days
and 28 days, and in original wild type and evolved mice we observed pathways
enriched in histone exchanges and chromatin remodeling, suggesting epigenetic
changes may differentiate the response of host and tumor. In black mice, we were
unable to isolate RNA from skin samples. Black mice tumor cells downregulated genes
that were previously annotated as involved in carcinogenesis, and metabolic pathways
in response to time and selection.
Conclusion: We conclude that transcriptomic changes are one strategy
underlying an organism’s resistance to cancer. These changes are important because
they can be targeted for cancer therapy once we identify the underlying mechanism. In
addition to de novo mutations, epigenetic alterations may have played a role in the arms
race between tumor and host, however further investigations are needed to confirm or
reject this possibility.

Introduction
Each division of somatic cells in a multicellular organism has some finite
probability of heritable genetic and nongenetic changes that can lead to loss of growth
control, hyperplasia, and eventually cancer (Nowell 1976; Stratton 2011; Berdasco and
Esteller 2010; Takeshima and Ushijima 2019; Gatenby, Gillies, and Brown 2010;
Levine, Jenkins, and Copeland 2019; Tomlinson, Novelli, and Bodmer 1996; Gatenby
and Brown 2017; Jones and Baylin 2007). Thus, it is not surprising that complex
organisms, such as mammals, manifest diverse cancer suppression mechanisms
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(Abegglen et al. 2015). Cancer progression is a Darwinian process, such that its
development and resistance to therapy are governed by natural selection and ecoevolutionary dynamics (Merlo et al. 2006b; Michor, Iwasa, and Nowak 2004; Maley,
Reid, and Forrest 2004; Gatenby and Brown 2020; Tollis, Boddy, and Maley 2017;
Fargam Neinavaie 2021; Pressley 2021). This creates an “evolutionary arms race”
between the cancer cells and the tumor suppressor mechanisms of the host (IbrahimHashim et al. 2021). However, one important dynamic in this system is the difference in
evolutionary scale between the cancer cells and the hosts. While the cancer cells
evolve only within the host, the host’s cancer suppressor strategies evolve across
generations. Host lineages are potentially subject to maintaining the disease because of
the disease only manifests after reproduction (Ellison 2014). In addition, there is a
tradeoff between health and fitness since energy used for reproduction may be at the
expense of processes such as immune function (Alföldi and Lindblad-Toh 2013;
Deerenberg et al. 1997). Hence, diseases that manifest after reproductive ages are less
visible to selection (Benton et al. 2021).
To mechanistically investigate these dynamics, we conducted two experiments in
which we selected immuno-deficient (severe combined immunodeficiency disease or
SCID) and immuno-competent (C57BL/6 or black) mice for resistance to the growth of
implanted Lewis’ lung (mouse) cancer tumor (LL/2-Luc-M38) (Ibrahim-Hashim et al.
2021). We observed that the two hosts evolved cancer suppression through two
different strategies. The SCID mice had increased growth of mesenchymal cells
(particularly fibroblasts) to infiltrate and encapsulate the cancer cells, and thus
mechanically suppress their proliferation. In contrast, black mice enhanced their
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immunologic response to tumor antigens through increased splenocyte proliferation and
tumor-specific cell killing. However, suppression was short-lived. If the mice in both
accessions were maintained beyond 11 days, tumor growth rapidly accelerated.
Evolutionary dynamics are typically governed by interactions of environmental
selection and the heritable phenotypic properties of the evolving organism. Many cancer
therapies can explicitly target the molecular machinery that underlies the selected
phenotype. Thus, our translational goals were to identify the genomic changes that are
related to the mechanisms underlying the evolution of increased resistance of the host
in response to the cancer cells as well as the cancer cells in response to evolved
changes in the host. Recognizing that these mechanisms can be genetic or nongenetic
molecular processes, we focused on how these processes translate into differences in
gene expression.
Using the power of RNA sequencing, we profiled changes in the patterns of gene
expression that manifest in response to the cancer cells after selection for resistance for
both the SCID and the black mice over time. We also profiled samples from the cancer
cells to identify differences in response to the evolved resistance in both host
genotypes. Since our preliminary results in SCID mice showed higher deposition of
collagen in evolved skin and tumors, we hypothesized that the intrinsic biomechanical
forces in collagen may modulate extracellular matrix (ECM), producing either protective
or disruptive molecular and cellular events during tumor progression (Lu et al. 2011).
Thus, we predicted increased expression of genes involved in ECM disrupting proteins
such as cathepsins, metalloproteases (MMPs), and Lysyl oxidase (LO) in both mouse
skin and tumors. Alternatively, the expression of ECM binding proteins (integrins, FbN
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receptors) may be suppressed. In the black mice, we expected an increase in the
expression of genes involved in innate immunosuppressive surface molecules in the EV
compared to the WT mice, since slower growth was observed in the preliminary data at
days 5-7 (Ibrahim-Hashim et al. 2021). We considered that this type of response was
too early to be a T cell response and was likely instead to be a better innate immune
response against the tumor. Alternatively, the counter strategies could include an
increase in expression of cellular proliferation pathways or a decrease in expression of
antigenic pathways since both are vital for immune response (Stockmann et al. 2014;
Gillies et al. 2018). Other alternatives would be upregulation of metabolic suppressors
of immunity, such as those leading to acidosis or hypoxia, either of which is
immunosuppressive (Damgaci et al. 2020; Damgaci et al. 2018b; Ibrahim-Hashim and
Estrella 2019). We found support for expression of some of these candidate genes and
dynamics of genetic pathways in our previous microarray study on tumors isolating from
the mice. However, RNASeq allowed for exploration of the subtle interactions of these
pathways with other gene networks, and how they may be finely tuned or exhibit novel
behavior during the evolution of different resistance strategies (Alvarez, Schrey, and
Richards 2015). This is partly because microarray techniques profile predefined genes
through hybridization, while RNA-seq includes all of the transcripts expressed at the
time of sampling. Our approach allows for discovery of novel interactions in response to
treatment with genes that may not be represented on the microarray. We predicted that
RNAseq would allow for identifying more associations of transcriptome wide responses
with our treatments of interest: accession and response to selection in mice and tumors.
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We also expected to discover new insight into the “arms race” by comparing expression
patterns in both the host tissue as well the tumor.

Materials and methods
Cell lines, Animal model, and Experimental cohorts
We obtained LL/2-luc-M38 (Lewis Lung carcinoma) cells from Xenogen
Corporation (Alameda CA). We authenticated the cells by short tandem repeat analysis,
and we confirmed they were free of mycoplasm. We grew and maintained the LL/2-lucM38 cells in Dulbecco's Modified Eagle Medium (DMEM/F12) supplemented with 10%
fetal bovine serum (HyClone) and 1% Penicillin and Streptomycin solution (pen strep)
(Corning). For this study, the wild type SCID mice were acquired from Charles River
(Wilmington, MA), and the evolved SCID mice were rederived form frozen deposited
embryo from the previous study(Ibrahim-Hashim et al. 2021) .We then injected EV and
WT SCID male mice on the right flank with LL/2-luc-M38 cells at 6 weeks of age. To be
certain the observed effects were due to host evolution and not tumor cell evolution over
the course of the experiment, we had expanded the LL/2-luc-M38 cells prior to the
experiments and divided the populations into aliquots of 5x10 5 cells in 200µL phosphate
buffered saline (PBS), which were stored at -80oC. After inoculations, we measured
tumor volume with caliper at days 0, 3, 10, 14, 21.
As published previously (Ibrahim-Hashim et al. 2021), at each round we
implanted a fixed number of LL/2-Luc-M38 cells in 10 male SCID and 10 male black
mice. We measured tumor growth and selected the two animals that exhibited the
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slowest tumor growth on day 11 for breeding. We used the male progeny as hosts in the
subsequent round.
Skin and tumor cells isolation
We collected skin and tumor samples from the SCID and black mice at 11 days
(the point at which EV mice had evolved resistance in our previous study), and 28 days
(a point where cancer cells may manifest more expansive counter-adaptations) we froze
down skin and tumor samples from black mice by storing them at -80°C for further
analysis.
We processed the collected skin and tumor samples immediately from SCID
mice after resection by mechanical dis-aggregation and from previously frozen black
mice samples. We placed skin and tumor tissues in sterile 10cm culture dishes and
washed them in Dulbecco's phosphate-buffered saline (DPBS). We minced skin and
tumor samples into 2-3 mm fragments and placed them in a 60mm sterile tissue culture
dish. We then dis-aggregated the tissues by mechanical pressure using the sterile blunt
end of a syringe handle. We extracted RNA from the resulting cell suspensions for each
skin and tumor sample using the Qiagen RNeasy kit following the manufacturer’s
protocol (Qiagen, Inc., Germantown, MD). We screened each extraction for quality on
an Agilent TapeStation (Agilent Technologies, Santa Clara, CA).
RNA-sequencing and QC analysis
The Moffitt core facility (genomics core) prepared the samples for RNAsequencing using the NuGen Ovation Mouse RNA-Seq System (NuGen Inc., San
Carlos, CA). Briefly, they used 100 ng of RNA to generate cDNA and a strand-specific
library following the manufacturer’s protocol. They performed quality control steps
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including Tape Station library assessment and quantitative RT-PCR for library
quantification. They sequenced the libraries on the Illumina NextSeq 500 v2.5
sequencer with 2 X 75-base paired-end high output runs in order to generate 40-50
million read pairs per sample.
The core completed pre- and post-alignment QC of the sequenced reads before
mapping them against mouse reference genome (mm10), using STAR-2.5.3a following
adaptor trimming by cutadapt (v.1.8.1). They determined gene-level quantification with
HTSeq 0.6.1 by summation of raw counts of reads aligned to the region associated with
each gene. They used Gencode, vM21 for gene models and used the script htseq-count
to count how many aligned reads overlapped the exons for each gene. They used these
counts for gene-level differential expression analyses in DESeq2 (Biswas et al. 2021).
Only reads mapping unambiguously to a single gene were counted, whereas reads
aligned to multiple positions or that overlapped with more than one gene were discarded
(Anders, Pyl, and Huber 2014). They normalized read counts of all samples using the
median-of-ratios method implemented in R/Bioconductor package DESeq2 v1.6.3. This
required creating a pseudo-reference sample (row-wise geometric mean), then
calculating the ratio of each sample to the references, followed by calculating the
normalization factor for each sample (size factor), and finally, calculating the normalized
count values using the normalization factor.
Quantitative Real Time PCR validation
We performed RT-PCRs on a 7900HT Fast-Real-Time System (Life
Technologies Applied Biosystems®) using an iScript Real-Time PCR kit with SYBR
Green (BioRad, 170-8893) to quantify the expression of the candidate genes after the
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genome-wide survey of expression. We used the same RNA that was sent for RNAseq
with 100 ng of mRNA per 20 µL reaction. We used GAPDH expression as an internal
control and normalized the expression of the candidate genes by calculating the ratios
against GAPDH expression levels. We obtained primers for Tripartite Motif Containing 6
(TRIMP6) from integrated DNA Technologies (Coralville, IA): F-5′AAGAATGCAAACTTAGAGGTAGTT -3′,R- 5′- TTTTCTCTAGTTACTGAGATACTTGTG
-3′.
Statistical analyses
The Moffit core used DESeq2 (Biswas et al. 2021) to perform differential
expression analysis on the normalized data. They used the two-way ANOVA to explain
if different time points (11days and 28 days) and different selection type original wild
type (WT) or evolved (EV) predicted significant differences in gene expression with the
model gene expression= time + type+ time*type. They adjusted p-values for multiple
testing with the Benjamini-Hochberg false discovery correction (Benjamini and
Hochberg 1995; Benjamini 2010)) and used a value of less than 0.1 (and/or a fold
change of 2 and above) to determine significance for differential expression.
The core used GeneGo MetaCore Software (Version 6.31 build 68930, Thomson
Reuters) to conduct pathway enrichment analysis using a False Discovery Rate (FDR)
of less than 0.1. They calculated the p-value and FDR for each pathway map in
iFTSEC283 and iOSE11 cells for upregulated and downregulated differentially
expressed genes from 4 SCID pairwise comparison groups: in skin vs. tumor; 1) EV at
11 days; 2) WT at 11days; 3) EV at 28 days; and 4) WT at 28 days. They selected
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genes (p-adj<=0.05) with log (FC) >= 1 and log (FC) <=-1 for up-regulated and downregulated pathway enrichment analysis, respectively.
For qPCR tests of means, we used Student’s t-tests where a p-value of < 0.05
was considered statistically significant (Prism 5 software).

Results
Phenotypic response
As reported in Ibrahim-Hashim et al. (2021), the evolved mice showed
significantly reduced tumor growth rates (P=0.02, t8=2.666) compared to the
contemporaneous control mice at 11 days, and growth accelerated after 14 days
(Figure 5.1 A). This is an important confirmation of our previous results (IbrahimHashim et al. 2021).
RNA QC
Overall, we isolated RNA from 36 samples. We were unable to isolate RNA from
any of the frozen skin from black mice. Also, out of 24 SCID we had to eliminate 9
samples, 4 from skin and 5 from tumor, and out of 12 black tumor samples, we had to
eliminate one sample due to missing or very low codon data alignment. We deemed the
quality of those sample as too low to be used for further analysis. (Figure 5.2 A, and
B). We confirmed these samples as outliers using principal component analysis (PCA;
figure 5.3, A and B).
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Differential gene expression profiles between tumor cell and host in immunecompromised SCID mice
We examined the mechanisms that evolved in the SCID mice over 10 mouse
generations and the countermeasures that evolved in the cancer cells that evolved
within the current mouse generation. From a total of 33,940 expressed genes, we
identified 6071 differentially expressed genes (DEG) in the skin (host) and 1353 DEG in
tumor cells when comparing 11 days to 28 days regardless of selection type.
Comparison of EV and WT mice revealed 98 DEG in skin and 32 in tumor cells (Figure
5.4 A).
In the SCID mice skin tissue, the genes responding over time included
upregulation of metabolic pathway gene like Carbonic anhydrase III(Car3), insulin like
growth factor binding protein 5 (Igfbp5), and Perilipin 1(Plin1). In the tumor cells, the
DEGs over time included extracellular matrix (ECM) remolding pathway, mainly the
metalloproteases gene family (MMPs) including MMP8, MMP9, MMP23, MMP2, and
MMP12, MMP3 and MMP5, Col6a6 and Col5a2.
In the SCID mice skin tissue, the DEGs between evolved and WT included
MicroRNAs, mainly MiR-7, and Mir5125. In the tumor cells, the DEGs were included in
ECM remodeling pathway, genes coding for different isotypes of collagen, mainly
collagen Col1a2. See also the top 15 DEG in Table5.2.
Functional categorization of DEG in four pairwise comparisons of SCID samples
We were completed gene ontology functional analysis of the DEG from skin and
tumors isolated only from SCID mice. When we compared 1) skin and tumor in the
evolved mice (EV skin v. EV tumor) at 11 days, analysis of “biological processes”
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showed enrichment for pathways in DNA replication, nucleosome processes, histone
exchange, cell cycle, and DNA replication in upregulated genes. However, pathways for
downregulated genes in the same comparison showed pathways involved in muscle
contractions and organization (Figure 5.5 A and B). In the comparison of 2) skin and
tumor in the original wild type mice (WT skin vs. WT tumor) at 11 days, analyses
showed enrichment for pathways involved in chromatin remodeling, centrosome
complex assembly, and DNA replication in upregulated genes, and enrichment
pathways involved in skin development and cell-cell adhesion in downregulated genes
(Figure 5.5 C and D). At 28 days, we compared 3) skin and tumor in the evolved mice
(EV skin v. EV tumor). Analyses of these mice showed no significant enrichment in the
upregulated genes; however, the downregulated genes were enrichmed for pathways
involved in epidermis development, skin development, and tight junction assembly
(Figure 5.6 A). In comparison of 4) skin and tumor in the original wild type mice (WT
skin vs. WT tumor) at 28 days, we found biological processes were enriched in
extracellular matrix organization, skin and epidermis development, epithelial cell
development, and cell migration pathways in down regulated genes. Upregulated genes
were enriched in ribosomal RNA (rRNA) processes, rRNA translation, rRNA processes,
ncRNA processing (Figure 5.6 B and C).
Differential gene expression profiles in immunocompetent black mice
From 47,919 total genes, we identified only 27 DEG between 11 days and 28
days, seven upregulated and 20 downregulated. We also found eight upregulated
genes in evolved tumors compared to WT (Figure 5.7 A). Genes involved in metabolic
pathways such as Car2 (carbonic anhydrase 2)(Mboge et al. 2018; Noor et al. 2018),
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and Bpgm (Bisphosphoglycerate Mutase)(Oslund et al. 2017) were upregulated across
time. Furthermore, genes that have been previously identified to play a role in
carcinogenesis were upregulated, including tripartite motif-containing 6 (TRIM6) (Willier
et al. 2011; Yang, Li, et al. 2020) and Slc22a15 (Solute Carrier Family 22 Member
1)(Zhu et al. 2019; Sarvagalla, Kolapalli, and Vallabhapurapu 2019) in response to
selection (see also the top 15 upregulated and downregulated genes in response to
time and selection; Table 5.2). We validated the expression of TRIM6 by RT-PCR and
demonstrate a significant (*p=0.037) decrease in expression in black evolved mice at 11
day (Figure 5.7 B).

Discussion
Several studies have demonstrated that there are some common strategies
launched by a host in response to cancer cells (Ibrahim-Hashim et al. 2017; Michod and
Roze 2001; Gatenby, Gillies, and Brown 2010). Yet, less is understood about how
strategies might vary across genetic backgrounds (Ibrahim-Hashim et al. 2021). Hence,
in this study, we investigated the transcriptomic changes that developed in two different
accessions with dramatically different physiological response to cancer. We also
evaluated the counterstrategy that cancer cells deploy in an attempt to understand the
mechanism underlying this “evolutionary arms race”. We used lines of SCID mice and
black mice that we experimentally bred to resist cancer progression. Using these two
very different strains provided insight into a wide range of available tumor suppression
strategies that can be used for targeted therapy.
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In SCID mice, only four genes were significantly downregulated in the tumor of
the evolved mice. However, an important finding is the downregulation of Col12a1,
which we identified in our previous study as well (Ibrahim-Hashim et al. 2021). This
small protein belongs to the fibril-associated collagen family and its overexpression has
been shown to play an important role in resistance to cancer treatments (Sun et al.
2015). The suppressed expression of this ECM binding protein might help explain our
results that show higher deposition of collagen in evolved skin samples from both
experiments that we performed (Xu et al. 2019; Nissen, Karsdal, and Willumsen 2019).
We also showed that at 28 days, when tumor growth accelerated, ECM disrupting
protein MMP8 was upregulated in the tumor samples. Metalloproteases (MMPs) are
enzymes that play an important role in extracellular matrix remodeling (Itoh and Nagase
2002; Lu et al. 2011), The activation of these enzymes is responsible for the
degradation of ECM, which enhance tumor immigration and invasion (Curran and
Murray 1999). MMP8 has been detected in breast, skin, liver and gastric cancers
(Juurikka et al. 2019).
In SCID skin samples between evolved and WT, we did not identify any genes
that have been previously related to cancer or involved in the remodeling of ECM.
However, the functional pathways analysis of the upregulated genes identified pathways
enriched in possible epigenetic modification, such as “histone exchanges pathway”
(Audia and Campbell 2016; Kurdistani 2007), and “chromatin remodeling pathway”
(Füllgrabe, Kavanagh, and Joseph 2011; Nair and Kumar 2012). These findings
suggest that instead of specific candidate gene expression differences, broader
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epigenetic mechanisms may be important for response. Future work is required to link
the patterns of the DEG we identified with regulatory epigenetic mechanisms.
Among the upregulated genes that we identified in the evolved black tumors that
play a role in carcinogenesis is TRIM6. TRIM6 belongs to the tripartite motif-containing
(TRIM) superfamily, is known to be expressed in response to interferons (IFNs) and are
involved in a broad range of biological processes that are associated with innate
immunity (Reymond et al. 2001; Rajsbaum, Stoye, and O'Garra 2008; Ozato et al.
2008). We observed slower tumor growth in evolved black mice in our previous work at
day 5-7 which is a bit early for a T cell response (Ibrahim-Hashim et al. 2021). This
response suggested a better innate immune response against the tumor. Hence,
expression of innate immunosuppressive surface molecules through e.g., the
expression of TRIM6 in the evolved mice could be a possible mechanism for this
increased resistance (Yang, Gu, et al. 2020). In contrast, black mice enhanced their
immunologic response to tumor antigens through increased splenocyte proliferation and
tumor-specific cell killing (Ibrahim-Hashim et al. 2021). Since the tumors of black mice
were frozen tumors generated in the previous study, their response can be related to
the mice response in the previous study.
This study confirms several findings that we identified in our previous
microarray study (Ibrahim-Hashim et al. 2021). In addition, we identified new interesting
genes that can contribute to resistance and can be targeted, e.g., specifically TRIM6.
We were also able to examine the subtle interactions of these genes with other gene
networks using gene ontology. Moving forward, we will need experimental validation of
the targets by overexpressing or knocking-down experiments in the context of controlled
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studies. We were not able to specifically investigate epigenetic mechanisms underlying
the tumor – host evolutionary arm race, but the expression differences we detected
could result from genetic and nongenetic mechanisms. The differential expression of
several components of the epigenetic machinery we detected suggest that investigating
epigenetic mechanisms could be an important future direction.
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Tables and figures
Table 5.1 RNA isolated sample ID.
SCID mice

Black mice

Skin RNA samples

Tumor RNA samples

Tumor RNA samples

S26- WT 11days

S14- WT 11days

S01- WT 11days

S27- WT 11days

S15- WT 11days

S02- WT 11days

S28- WT 11days

S16- WT 11days

S03- WT 11days

S29- EV 11days

S17- EV 11days

S04- EV 11days

S30- EV 11days

S18- EV 11days

S05- EV 11days

S31- EV 11days

S19- EV 11days

S06- EV 11days

S32- WT 28days

S20- WT 28days

S07- WT 28days

S33- WT 28days

S21- WT 28days

S08- WT 28days

S34- WT 28days

S22- WT 28days

S09- WT 28dyas

S35- EV 28days

S23- EV 28days

S10- EV 28days

S36- EV 28days

S24- EV 28days

S11- EV 28days

S37- EV 28days

S25- EV 28days

S12- EV 28days

S = Sample; WT = wild type; EV = evolved.
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Table 5.2. Top 15 genes downregulated and upregulated in SCID skin and tumor, and black
mice tumor in response to type factor (EV vs WT) and time factor (11days vs. 28 days).
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Figure 5.1 Comparison of tumor growth in Non-evolved SCID mice (n = 5) and in Evolved SCID
mice (n = 5). There was a significant difference in the tumor growth starting at 7 days and at 11
days post injection of Non-Evolved (WT) and Evolved SCID mice but not at 14 days. Mean+/SEM is plotted with significance-based Student t test.
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Figure 5.2 Alignment distribution showing the percentage of bases mapped to the deferent
regions from A SCID RNA samples isolated from skin and tumors, and B Black RNA samples
isolated from tumor, Regions are color-coded: coding, UTR (untranslated region), intron, and
intergenic.
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Figure 5.3 Principal component (PC) analysis plot displaying A all the 24 SCID samples along
PC1 and PC2, which describe 59.43% and 11.78% of the variability, respectively, within the
expression data set. PC analysis was applied to normalized (reads per kilobases of transcript
per 1 million mapped reads) and log-transformed count data B. all 12 black samples along PC1
and PC2, which describe 76.98% and 15.96% of the variability, respectively, within the
expression data set.
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Figure 5.4 A Numbers of upregulated and down regulated genes in repose to time and
selection factors is SCID mice skin and tumor samples. Red bar is upregulated, and green bar
is down regulated
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Figure 5.5 Bar chart of the top ten significant GO biological processes associated with SCID
mice skin and tumor pairwise comparison in A upregulated, B downregulated EV at 11days and
C upregulated, D down-regulated WT in 11d days. EV= evolved, WT= wild type
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Figure 5.6 Bar chart of the top ten significant GO biological processes associated with SCID
mice skin and tumor pairwise comparison in A downregulated EV at 28days, B upregulated and
C downregulated WT in 28 d days. EV= evolved, WT= wild type
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Figure 5.7 A Numbers of upregulated and down regulated genes in black mice in response to
time and selection factors. Red bar is upregulated, and green bar is down regulated. B RT-PCR
showing significantly (p=0.037) decreased expression of TRIM6 in Evolved black mice (n=3)
compared to LL/2. Mean+/- SEM is plotted. A 2 tailed unpaired Student’s t-test was employed.
WT (wild type)
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CHAPTER 6
CONCLUSION

You have cancer! The sentence that no one wants to hear. This devastating disease
is horrifying as well as interesting. Horrifying in the way that it kills most people who are
diagnosed with it, and interesting because of its ability to arise from one’s own body and
in some sense become its own competitor. Indeed, it is challenging to explain how cancer
occurs and how it moves from one part of the body to another, but we need not be afraid
to think outside the box to understand it.
Molecular biology in particular, has advanced cancer research and drug discovery.
However, the failure of targeted therapy and drug resistance are a fundamental problem
in treating cancer and infectious diseases as well. The inevitable urgency to overcome
this resistance implores us to explore ways in which ecological and evolutionary theory
can inform our understanding of cancer. Cancer is a disease of somatic cells that acquire
different “somatically heritable deregulation of genes” (Baylin and Jones 2016). This
deregulation can result from heritable genetic or nongenetic changes: when the altered
cell divides, a copy of the genetic and nongenetic material is carried to daughter cells.
Those heritable changes affect proliferation and survival. Hence, Darwinian natural
selection plays a role in cancer initiation and progression such that cells with a higher
level of fitness, regardless of the underlying mechanisms of the heritable differences will
be favored(Bonduriansky and Day 2018; Richards and Pigliucci 2021).
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After briefly introducing my interest in research in Chapter 1, Chapter 2 is focused on
defining cancer as a speciation event. The focus of our perspective was how this
speciation event is governed by epigenetic mechanisms. The epigenetic changes
(epimutations) during tumorigenesis are complex and can involve multiple steps.
Compared to a genetic mutation, epimutations are reversible, making them a promising
therapeutic target to help reduce cancer. Understanding the interplay between genetic
and epigenetic changes in cancer and defining the cause and effect is yet a challenge
and a growing field to explore. Unfortunately, research in the field has been largely
focused on studying new mutations while we could get more out of the existing available
genetics and epigenetics data, and exploring the interaction between those data using
appropriate design and analytical tools (Fargam Neinavaie 2021).
We now know that cancer is more than just a sequence of sequence mutations; it is a
complex interaction of these mutations and nongenetic changes with the tumor
microenvironment. This microenvironment consists of cellular components such as
immune cells and fibroblasts and non-cellular components such as cytokines. Equilibrium
between cancer cells and their environment can shift to favor or disfavor the tumor growth
and metastasis. Immune cells in the tumor microenvironment play a critical role in
contributing to various hallmarks of cancer(Hanahan and Weinberg 2000, 2011). Immune
cells are also a double-edged sword; they can contribute to tumor prevention or tumor
surveillance. Chapter 3 focused on how anesthesia can compromise the immune system
as a critical component in the oncologic effect. We found that perturbing the immune
system with anesthetic pharmacologic agents enhanced tumor metastasis. Thus, by
combining strong immunomodulators with anesthetic in the perioperative period, the
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effects can be magnified. Attenuators of these inflammatory and stress responses, such
as immunostimulant agents, may prove beneficial. Further study is needed to test this
hypothesis.
Evolution is clever! when it comes to evolutionary pressure, when a novel solution
arises in a lineage that increases fitness that lineage carries on. Cancer cell populations
evolving within a host follow the same algorithm. Variable birth and death rates result in
temporal and spatial phenotypic differences in response to changing environmental
selection forces that govern tumor growth, response to therapy, and extinction.
In chapter 4 and chapter 5, we applied artificial selection to evolve a response that
steered cancer to a smaller and less aggressive phenotype. Host accessions rapidly
evolved immunologic (in black) and non-immunologic (in SCID) tumor defenses.
However, we also discovered that cancer cells maintain sufficient plasticity to deploy
effective phenotypic and population-based counterstrategies quickly.
Multiple dynamic adaptive process control cancer, and analysis of the genetic and
nongenetic mechanisms of these adaptive strategies will provide novel insights into the
evolutionary capacity of cancer cells that can provide a new direction for therapy. Finally,
the time has come to think unconventionally about utilizing evolutionary principles and
ecological approaches synergistically to increase our knowledge about the development
and treatment of cancer. This will create a useful framework that for sure will aid in
amplifying a patient’s own defense against cancer.
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